(Click sector to view stock chart)
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)
ZymoGenetics, Inc. engages in the discovery, development, and commercialization of therapeutic protein-based products for the treatment of human diseases. Its products include Novolin and NovoRapid marketed worldwide for the treatment of diabetes; NovoSeven marketed worldwide for the treatment of hemophilia; Regranex for the treatment of wound healing; GlucaGen for use as an aid for gastrointestinal motility inhibition and for the treatment of severe hypoglycemia in diabetic patients treated with insulin; and Cleactor for the treatment of myocardial infarction or heart attacks. The company's product pipeline comprises rhThrombin, TACI-Ig, and IL-21. rhThrombin is a topical hemostatic agent intended for the control of bleeding during surgical procedures has completed Phase 2 clinical trial. TACI-Ig is a soluble receptor for the treatment of autoimmune diseases and is developed in collaboration with Serono S.A. IL-21 is a protein for the treatment of cancer. ZymoGenetics was co-founded by Earl W. Davie, Benjamin D. Hall, and Michael Smith in 1981. The company is headquartered in Seattle, Washington.
CytRx Corporation, a biopharmaceutical company, engages in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference (RNAi). It owns 3 clinical-stage compounds based on its small molecule molecular chaperone' co-induction technology, as well as a targeted library of 500 small molecule drug candidates that would be used to screen for new drug candidates. The company initiated a Phase II clinical trial with its lead small molecule product candidate, Arimoclomol for the treatment for amyotrophic lateral sclerosis (ALS). Arimoclomol received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration. CytRx has also licensed from the University of Massachusetts Medical School (UMMS) the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology, which demonstrated positive interim Phase I clinical trial results indicating its ability to produce potent antibody responses with neutralizing activity against multiple HIV viral strains. The company has a strategic alliance with UMMS to develop compounds in the areas of ALS, obesity, type II diabetes, and cytomegalovirus using RNAi technology, as well as a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. CytRx was incorporated in 1985 and is headquartered in Los Angeles, California.
SCHERING-PLOUGH CORP (SGP)
Schering-Plough Corporation engages in the discovery, development, manufacture, and marketing of medical therapies and treatments primarily in the United States, Canada, and Europe. The company also markets consumer brands in the over-the-counter (OTC), foot care, and sun care markets, as well as operates a global animal health business. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. The Prescription Pharmaceuticals segment manufactures and markets primary care products that include allergy/ respiratory, antibiotics, dermatologicals, and erectile dysfunction products, as well as specialty care products, such as anti-infectives, anti-inflammatories, oncology, acute coronary care, and other products for humans. It sells its products to hospitals, certain managed care organizations, wholesale distributors, and retail pharmacists. The Consumer Health Care segment manufactures and markets OTC, foot care, and sun care products. It sells its products through wholesale and retail drug, food chain, and mass merchandiser outlets. The Animal Health segment manufactures and markets animal health products to the livestock, poultry, companion animal, and aquaculture markets. It sells its products to veterinarians, distributors, and animal producers. Schering-Plough Corp. has a collaboration and license agreement with OncoMethylome Sciences for Schering-Plough to utilize assay technology from OncoMethylome Sciences that measures the methylation status of the MGMT gene in patients with glioblastoma multiforme, a form of malignant brain cancer, treated with temodar. The company was incorporated in 1970 and is headquartered in Kenilworth, New Jersey.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of generic and human drugs worldwide. Its generic pharmaceutical products include tablets, capsules, ointments, creams, liquids, and injectables. The company's active pharmaceutical ingredients include peptide active pharmaceutical ingredients. It also develops technologies, such as fermentation processes. The company has strategic alliances with Biovail Corporation International, Savient Pharmaceuticals, Inc., Impax Laboratories, Inc., and Andrx Corporation. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
BRISTOL-MYERS SQUIBB COMPANY (BMY)
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, license, manufacture, marketing, distribution, and sale of pharmaceutical and other health care products. The company primarily operates in three segments: Pharmaceuticals, Nutritionals, and Other Healthcare. The Pharmaceuticals segment provides branded pharmaceutical products for cardiovascular, virology, including human immunodeficiency virus, infectious diseases, oncology, affective disorders, and metabolics. It offers its products primarily to wholesalers, retail pharmacies, hospitals, government entities, and the medical professionals. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products, including a line of ENFAMIL products. The nutritional products are generally sold by wholesalers and retailers to healthcare professionals. The company's Other Healthcare segment consists of ConvaTec, Medical Imaging, and Consumer Medicines businesses. ConvaTec provides ostomy, and wound and skin care products. Medical Imaging offers cardiovascular imaging products, including radiopharmaceuticals and ultra-sound agents. Consumer Medicines provides consumer health care products for headache relief, analgesics, cold, cough, flu, and moisturizers, as well as for diabetics. BMS has strategic alliances with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; and Sankyo Company, Ltd. The company has a collaboration agreement with Ambit to discover kinase inhibitors; and with Domantis Limited to develop dAb therapeutics for uses in the fields of immunology and oncology. The company was founded in 1887. It was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers is headquartered in the New York City.
ELAN CORPORATION PLC (ELN)
Elan Corporation, plc engages in the discovery, development, manufacture, and marketing of advanced therapies in autoimmune diseases, such as pain and neurodegenerative diseases. The company operates in two segments, Biopharmaceuticals, and Global Services and Operations. The Biopharmaceuticals segment engages in biopharmaceutical research, development, and commercialization activities, which include the discovery and development of products in the therapeutic areas of neurology, autoimmune diseases, and pain. Its pharmaceutical commercial activities consists of the marketing of neurology/pain management products, including Myobloc that acts at the neuromuscular junction to produce flaccid paralysis; Zanaflex, which is used in the treatment of partial epileptic seizures in adults; and Frova that is used as an antimigraine therapy. This segment also markets various hospital products, such as Maxipime, an antibiotic that is used to treat patients with infections; and Azactam, which is used to treat pneumonia, post surgical infections, and septicemia. The Global Services and Operations segment focuses on product development and manufacturing to provide drug delivery technologies for the pharmaceutical industry. The company sells its pharmaceutical products primarily to drug wholesalers; and drug delivery products for licensees and distributors in the United States, the United Kingdom, and Ireland. Elan has collaboration agreement with Wyeth. The company was incorporated in 1969 and is headquartered in Dublin, Ireland.
Novartis AG engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in three divisions: Pharmaceuticals, Consumer Health, and Sandoz. Pharmaceuticals division develops, markets, and sells branded pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism, neuroscience, respiratory and dermatology, specialty medicines, oncology and hematology, transplantation and immunology, and ophthalmic diseases, as well as arthritis, bone, gastrointestinal, hormone replacement therapy, and infectious diseases. Consumer Health division operates five units, such as over-the-counter self-medication products, animal health, medical nutrition, infant and baby foods, and lens and vision care. Sandoz division develops, manufactures, markets, and sells retail generics drugs, and off-patent active pharmaceutical ingredients and intermediates to wholesalers, pharmacies, hospitals, and other healthcare outlets. It also provides biopharmaceutical products, such as protein hormones and other human proteins. Novartis has a collaboration agreement with Alnylam Pharmaceuticals, Inc. focused on the discovery of therapeutics based on RNA interference; with Avalon to discover and develop small molecule therapeutics for an undisclosed indication; with Vernalis plc focused on the oncology target Hsp90; with Ablynx nv to discover and develop therapeutic Nanobodies; and with Ono Pharmaceutical Co., Ltd. to develop and market rivastigmine transdermal patch in Japan for the treatment of Alzheimer's disease. The company sells its products to physicians, pharmacists, hospitals, insurance groups, and managed care organizations. Novartis was formed in 1895 and is headquartered in Basel, Switzerland.
ABBOTT LABORATORIES (ABT)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a line of health care products principally in the United States and Canada. The company operates through three segments: Pharmaceutical Products, Diagnostic Products, and Ross Products. The Pharmaceutical Products segment's products include a line of adult and pediatric pharmaceuticals, which are sold primarily on the prescription, or recommendation, of physicians. This segment sells its products directly to wholesalers, government agencies, health care facilities, and independent retailers in the United States through company-owned distribution centers and public warehouses. The Diagnostic Products segment's products consist of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and consumers. These products are sold directly to hospitals, laboratories, clinics, and physicians' offices. The Ross Products segment's products include a line of pediatric and adult nutritionals. This segment sells its products directly to physicians, health care facilities, and government agencies through wholesalers. Abbott Laboratories has a strategic alliance with Myriad Genetics, Inc. in pharmacogenetics that would focus on identifying human genetic variation around drug targets in various stages of development. The company was founded by Wallace Calvin Abbott in 1888. Abbott Laboratories is based in Abbott Park, Illinois.
FOREST LABORATORIES INC (FRX)
Forest Laboratories, Inc. engages in the development, manufacture, and sale of both branded and generic forms of ethical drug products, as well as nonprescription pharmaceutical products sold over-the-counter. The company's products include Lexapro, Celexa, Namenda, Tiazac, Benicar, Benicar HCT, Milnacipran, CCR1, Lercanidipine, Campral, and Combunox. The Lexapro and Celexa are used for the initial and maintenance treatment of depressive disorders, and for generalized anxiety disorders. The Namenda, an N-methyl-D-aspartate-receptor antagonist, is used for the treatment of moderate to severe Alzheimer's disease. The Tiazac, Benicar, Benicar HCT, and Lercanidipine are used for hypertension. The Milnacipran is in Phase III development for the treatment of fibromyalgia syndrome. The CCR1 is a chemokine receptor involved in the inflammation process. Campral is used for the maintenance of abstinence from alcohol in patients with alcohol dependence. Combunox, an opioid and NSAID combination, is used for the short-term management of pain. It also has various products under development, which include RGH-188 in Phase I clinical trials, an atypical antipsychotic for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions; phase I completed GRC 3886, a novel, orally available Phosphodiesterase-IV inhibitor in development for chronic obstructive pulmonary disorder and asthma; and Desmoteplase, a novel plasminogen activator, or blood clot-dissolving agent. The company markets its products directly and though independent distributors worldwide to physicians, pharmacies, hospitals, managed care, and other healthcare organizations. The company has strategic alliances with H. Lundbeck A/S; Merz Pharma GmbH; Sankyo Pharma; Merck Sante s.a.s.; Gedeon Richter Ltd.; Glenmark Pharmaceuticals; PAION GmbH; ChemoCentryx, Inc.; Cypress Bioscience, Inc.; and Recordati, S.p.A. Forest Laboratories was organized in 1956 and is based in New York City.
Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals, as well as consumer healthcare products worldwide. It operates in three segments: Human Health, Consumer Healthcare, and Animal Health. The Human Health segment offers treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders, and allergies. The Consumer Healthcare segment markets over-the-counter medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care, and hair growth. Its principal products include Listerine mouthwash, Listerine PocketPaks oral care strips, Nicorette for tobacco dependence, Benadryl antihistamine for allergies, Sudafed for sinus congestion, Rogaine for hair growth, Zantac 75 for prevention and relief of heartburn, Rolaids antacid tablets, Efferdent denture cleaner, Neosporin antibiotic ointment, Visine eye drops, BenGay topical analgesic, Cortizone skin care products, Lubriderm moisturizing lotions, Unisom sleep aids, Desitin ointments for treatment of diaper rash, Ludens throat drops, and Purell instant hand sanitizer. The Animal Health segment offers products for the prevention and treatment of diseases in livestock and animals. Its products include parasiticides, anti-inflammatories, vaccines, antibiotics, and related medicines. In addition, the company offers empty soft-gelatin capsules, contract manufacturing, and bulk pharmaceutical chemicals. Pfizer has an agreement with Power 3 Medical Products, Inc. to evaluate the NuroPro test capabilities and to test blind and unblinded samples provided by Pfizer; and a research and license agreement with Incyte Corp. for the development, manufacture, and marketing of oral CCR2 antagonists. The company was founded in 1849 and is headquartered in New York City.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen has collaboration and license agreement with Memory Pharmaceuticals Corp. to produce drugs for neurological and psychiatric disorders; and a drug-discovery agreement with Galapagos Genomics NV. The company was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. Amgen is headquartered in Thousand Oaks, California.
ELI LILLY AND COMPANY (LLY)
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of primarily pharmaceutical products in the United States and internationally. The company's products include neuroscience products, which include Zyprexa, Prozac, Strattera, Cymbalta, Permax, Symbyax, and Yentreve; endocrinology products that consist primarily of Humalog, Humulin, Actos, Evista, Forteo, and Humatrope; and oncology products, which comprise primarily of Gemzar and Alimta. It also offers cardiovascular products that consist primarily of ReoPro and Xigris; and anti-infectives, which primarily include Ceclor and Vancocin. The other pharmaceutical product group includes Cialis, Axid, and other miscellaneous pharmaceutical products and services. In addition, Eli Lilly offers animal health products that include Tylan, Rumensin, Coban, and other products for livestock and poultry. It primarily sells its pharmaceutical products through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. Eli Lilly has a collaboration agreement with HistoRx, Inc. to apply the HistoRx AQUA platform for quantitative pathology analysis; and with Alkermes, Inc. to develop and commercialize inhaled formulations of parathyroid hormone for the treatment of osteoporosis. The company was founded by Eli Lilly in 1876 and is based in Indianapolis, Indiana.
GILEAD SCIENCES INC (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.
QUIDEL CORPORATION (QDEL)
Quidel Corporation engages in the development, manufacture, and marketing of point-of-care (POC) rapid diagnostic solutions for infectious diseases and reproductive health. Its POC and diagnostic tests include QuickVue, QuickVue+, QuickVue Advance, RapidVue, BlueTest, and Metra. These products provide diagnostic information for acute and chronic conditions that affect women and their family's health. The company offers POC diagnostics for infectious diseases, such as Influenza, Group A Strep, Helicobacter pylori, and Mononucleosis; Reproductive Health, which include Pregnancy, Chlamydia, and Bacterial Vaginosis; and Bone Health and Oncology. Quidel's products under development include Strep A web, respiratory syncitial virus test, LTF technology platforms, and QuickVue advance pH and amines test. The company incorporates immunoassay, enzymology, biochemistry, and microbiology technology into its diagnostic products. It markets its products to its customers through a network of distributors supported by a direct sales force in the United States, and through distributors and sales agents primarily in Japan, Europe, and Latin America. Quidel sells its products to professionals for use in physician offices, hospitals, clinical laboratories, and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, California.
HUMAN GENOME SCIENCES INC (HGSI)
Human Genome Sciences, Inc. operates as a biopharmaceutical company with a pipeline of novel protein and antibody drugs. The company's drugs in clinical development include LymphoStat-BTM for the treatment of lupus and rheumatoid arthritis; AlbuferonTM for the treatment of chronic hepatitis C; HGS-ETR1, HGS-ETR2, HGS-TR2J for the treatment of solid and hematopoietic cancers; CCR5 mAb for the treatment of HIV/ AIDS; and ABthraxTM for the treatment of anthrax infection. It has various strategic partners, including GlaxoSmithKline, Takeda, Schering-Plough, Sanofi-Synthelabo, Merck KGaA, Transgene, MedImmune, Inc., and Pharmacia & Upjohn. Human Genome Sciences was founded in 1992 and is headquartered in Rockville, Maryland.
INSITE VISION INCORPORATED (ISV)
InSite Vision Incorporated, an ophthalmic product development company, develops genetically-based technology for the diagnosis, prognosis, and management of glaucoma, ocular infections, and retinal diseases. The company also focuses on ophthalmic pharmaceutical products based on its DuraSite eyedrop-based drug delivery technology. Its principal product, AzaSite, targets infections of the eye. The company has research collaborations and licensing agreements with Societa Industria Farmaceutica Italiana-S.P.A; Quest Diagnostics Incorporated; CIBA Vision Ophthalmics; UC Regents; Columbia Laboratories, Inc.; Global Damon Pharm and Kukje Pharma Ind. Co., Ltd.; and SSP Co., Ltd. InSite Vision was incorporated in 1986 and is based in Alameda, California.
XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck & Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.
CELGENE CORPORATION (CELG)
Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.
MILLENNIUM PHARMACEUTICALS INC (MLNM)
Millennium Pharmaceuticals, Inc. engages in the research, development, and commercialization of therapeutic products in the areas of cancer, cardiovascular, and inflammatory diseases. The company's products include VELCADE, a proteasome inhibitor for treating patients with multiple myeloma; and INTEGRILIN injection, a cardiovascular product. Its INTEGRILIN injection prevents aggregation of blood platelets and occlusion of the arteries supplying the heart muscle with oxygen to prevent the incidence of heart attack or death in patients with acute coronary syndrome, and for the treatment of patients undergoing percutaneous coronary intervention. The company's preclinical and clinical development drug candidates include MLN2704 for prostate cancer; MLN518 for acute myeloid leukemia; MLN8054 for solid tumor cancers; MLN2222 for reperfusion injury in patients undergoing cardiac surgeries; MLN1202 for rheumatoid arthritis multiple sclerosis; MLN3897 for chronic inflammatory diseases, such as rheumatoid arthritis; MLN02 for Crohn's disease; and MLN3701 for chronic inflammatory diseases, such as rheumatoid arthritis. It has strategic alliances with Ortho Biotech Products, L.P.; Schering-Plough, Ltd.; GlaxoSmithKline plc; Aventis Pharma; and Schering Corporation. Millennium Pharmaceuticals was founded in 1993 and is headquartered in Cambridge, Massachusetts.
ADOLOR CORPORATION (ADLR)
Adolor Corporation, a development stage biopharmaceutical corporation, engages in the discovery, development, and commercialization of prescription pain management products primarily in the United States. Its lead product candidate, Entereg, is a small molecule, peripherally-acting mu opioid receptor antagonist. As of July 6, 2005, the company was under development of Entereg for the management of the gastrointestinal side effects associated with opioid use. Adolor other products under development include a sterile lidocaine patch, is in Phase 2 clinical development, for treating postoperative incisional pain, and analgesics for treating moderate-to-severe pain conditions. The company has collaboration agreement with Glaxo Group Limited for the development and commercialization of Entereg in multiple indications. It also has a license agreement with EpiCept Corporation to develop and commercialize a sterile lidocaine patch in North America. Adolor was formed in 1993 and is headquartered in Exton, Pennsylvania.
GENZYME CORPORATION (GENZ)
Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.
AtheroGenics, Inc. engages in the discovery, development, and commercialization of therapeutics for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis, and asthma. It owns a proprietary vascular protectant technology (v-protectant) platform to discover drugs to treat these types of diseases. Based on this v-protectant platform, the company has two drug development programs. The company's AGI-1067 is a v-protectant candidate that is designed to benefit patients with coronary heart disease, which is atherosclerosis of the blood vessels of the heart. Its AGI-1067 is also being evaluated in the pivotal Phase III clinical trials called ARISE, as an oral therapy for the treatment of atherosclerosis. AtheroGenics' AGI-1096, a v-protectant candidate, is an antioxidant and selective anti-inflammatory agent for accelerated inflammation of grafted blood vessels. AGI-1096 inhibits the expression of certain inflammatory proteins, including VCAM-1, in endothelial cells lining the inside surfaces of blood vessel walls. In addition, AtheroGenics has preclinical programs in rheumatoid arthritis and asthma using its v-protectant platform. The company has collaboration agreement with Astellas Pharma. AtheroGenics was organized in 1993 and is headquartered in Alpharetta, Georgia.
ARIAD PHARMACEUTICALS INC (ARIA)
ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. Its lead cancer product candidate, AP23573, is an mTOR inhibitor to treat solid tumors and hematologic malignancies. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. Two multicenter Phase Ib studies with AP23573 in combination with other anti-cancer therapies, which are underway in Europe, focus primarily on patients with breast, ovarian, non-small-cell lung, and prostate cancers, as well as certain sarcomas. ARIAD also has an exclusive license to technology and patents related to certain NF-kB treatment methods, as well as the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which might be useful in treating certain diseases. In addition, the company has a partnership with Medinol, Ltd., a cardiovascular medical device company, to develop and commercialize stents and other medical devices to deliver AP23573 to prevent reblockage of injured vessels following stent-assisted angioplasty, a common nonsurgical procedure for dilating or opening narrowed arteries. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.
KING PHARMACEUTICALS INC (KG)
King Pharmaceuticals, Inc. engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products. It offers various branded prescription products over seven therapeutic areas, including cardiovascular, endocrinology, neuroscience, critical care, anti-infective, respiratory, and other. The company also develops, manufactures, and sells auto-injectors for the self-administration of injectable drugs. In addition, King Pharmaceuticals provides contract pharmaceutical manufacturing services to third-party pharmaceutical and biotechnology companies, as well as transfers company's manufacturing and marketing rights to third parties for licensing fees or royalty payments. The company distributes its branded pharmaceutical products primarily through wholesale pharmaceutical distributors and pharmacies to general/family practitioners, internal medicine physicians, cardiologists, endocrinologists, psychiatrists, neurologists, pain specialists, sleep specialists, and hospitals across the United States and in Puerto Rico. King Pharmaceuticals has a strategic collaboration relating to Intal (cromolyn sodium) and Tilade (nedocromil sodium), which includes the development of a new formulation of Intal utilizing hydrofluoroalkane, an environmentally friendly propellant; and with Pain Therapeutics, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. King Pharmaceuticals was incorporated in 1993 and is headquartered in Bristol, Tennessee.
NABI BIOPHARMACEUTICALS (NABI)
Nabi Biopharmaceuticals engages in the development and commercialization of products in the areas of Gram-positive bacterial infections, hepatitis, nephrology, and nicotine addiction. The company markets three products: PhosLo for treatment of hyperphosphatemia in end-stage renal failure patients; Nabi-HB for the prevention of hepatitis B infections; and Aloprim for the treatment of chemotherapy-induced hyperuricemia or high uric acid levels. Nabi also has products in various stages of clinical and preclinical development. Its advanced StaphVAX, which is in Phase III clinical development, is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. The company's other products in development include Altastaph, an antibody for prevention of Staphylococcus aureus infections; NicVAX, a vaccine to treat nicotine addiction; and Civacir, an antibody for preventing hepatitis C virus reinfection in liver transplant patients. The company also offers contract manufacturing services. Nabi sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as sells its antibody products to pharmaceutical and diagnostic product manufacturers. The company has strategic alliances with Public Health Services/National Institutes of Health; Chiron Corporation; Pfizer; and Cambrex BioScience of Baltimore, Inc. Nabi is headquartered in Boca Raton, Florida.
MERCK & COMPANY INC (MRK)
Merck & Co., Inc. engages in the discovery, development, manufacture, and marketing of a range of products to improve human and animal health. The company's products consist of therapeutic and preventive agents, sold by prescription, for the treatment and prevention of human disorders. It offers atherosclerosis products, which include Zocor; hypertension/heart failure products, including Cozaar, Hyzaar, and Vasotec; anti-inflammatory/analgesics, agents that specifically inhibit the COX-2 enzyme, which is responsible for pain and inflammation; an osteoporosis product, Fosamax, for treatment and prevention of osteoporosis; a respiratory product, Singulair, a leukotriene receptor antagonist for treatment of asthma and for relief of symptoms of seasonal allergic rhinitis; vaccines/biologicals, a live virus vaccine of chickenpox and hepatitis B vaccine; anti-bacterial/anti-fungal products, which include Primaxin, Cancidas, and Invanz; a urology product, Proscar, for treatment of symptomatic benign prostate enlargement; and HIV products, including Stocrin and Crixivan for the treatment of human immunodeficiency viral infection in adults. Its other products include Maxalt, for the treatment of acute migraine headaches in adults; and Propecia, for the treatment of male pattern hair loss. Merck & Co. has a collaboration agreement with Celera Diagnostics to develop treatments for Alzheimer's disease; and with Foxhollow Technologies, Inc. to focus on analyzing atherosclerotic plaque removed from patient arteries as a means of identifying biomarkers of atherosclerotic disease progression for use in the development of cardiovascular compounds. The company sells its products to drug wholesalers and retailers; hospitals; clinics; government agencies; and managed health care providers, such as health maintenance organizations and other institutions through its professional representatives. Merck & Co. was established in 1891 and is headquartered in Whitehouse Station, New Jersey.
ONYX PHARMACEUTICALS INC (ONXX)
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer. Its primary product includes sorafenib, a Phase III orally available signal transduction inhibitor, inhibits proliferation of cancer cells and angiogenesis. In addition, sorafenib inhibits VEGFR-2 and PDGFR-ß, two proteins involved in angiogenesis, and other proteins that might be implicated in cancer. The company also develops PD 332991, a Phase I clinical trial product, a small molecule cell cycle inhibitor targeting a cyclin-dependent kinase. Onyx Pharmaceuticals has collaboration agreement with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity, of the RAS signaling pathway to treat cancer and other diseases. The company was established in 1992 and is headquartered in Emeryville, California.
Johnson & Johnson engages in the manufacture and sale of various products in the health care field primarily in the United States. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics (MDD). Consumer segment manufactures and markets a range of products used in the baby and child care, skin care, oral and wound care, and women's health care fields, as well as over-the-counter pharmaceutical and nutritional products. These products are marketed primarily to the general public; and sold to wholesalers, and directly to independent and chain retail outlets worldwide. Pharmaceutical segment franchises various products in the anti-fungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic, and urology fields. These products are distributed directly, and through wholesalers and health care professionals for use by prescription by the general public. MDD segment offers a range of products, including wound care and women's health products; minimally invasive surgical products; circulatory disease management products; blood glucose monitoring products; professional diagnostic products; orthopedic joint reconstruction, spinal, and sports medicine products; and disposable contact lenses. These products are distributed directly and through surgical suppliers and other dealers for use by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics. Johnson & Johnson has an agreement with Bayer AG to jointly develop and market a compound labelled BAY 59-7939 for the prevention and treatment of thrombosis. The company was founded by Robert Wood Johnson in 1887. Johnson & Johnson is headquartered in New Brunswick, New Jersey.
VERTEX PHARMACEUTICALS INCORPORATED (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in the discovery, development, and commercialization of small molecule drugs for HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, pain, and bacterial infection. It offers Lexiva/Telzir and Agenerase for HIV infection. The company is developing Merimepodib and VX-950, which are in phase I and phase II stage; VX-765, VX-702, and Pralnacasan that are in phase II stage; VX-680, VX-944, and VX-322, which are in phase I and preclinical stage; and VX-409 and VX-692, that are in preclinical stage. Vertex Pharmaceuticals has collaboration agreements with Aventis S.A.; GlaxoSmithKline plc; Novartis Pharma AG; Merck & Co., Inc.; Mitsubishi Pharma Corp.; and Cystic Fibrosis Foundation Therapeutics Incorporated. It also has collaboration agreements with Schering AG; Kissei Pharmaceutical Co., Ltd.; and Eli Lilly and Company. In addition, it has a licensing agreement with Avalon Pharmaceuticals, Inc. for the development and commercialization of the IMPDH inhibitor VX-944 for the treatment of cancer. Vertex Pharmaceuticals was founded by Joshua Boger in 1989 and is headquartered in Cambridge, Massachusetts.
Genentech, Inc., a biotechnology company, engages in the discovery, development, manufacture, and commercialization of biotherapeutics for medical needs. It manufactures and commercializes multiple products for a variety of medical conditions, including cancer, heart attack, allergic asthma, psoriasis, stroke, growth hormone deficiency, and cystic fibrosis in the United States. The company's product portfolio comprises Rituxan, an anti-CD20 antibody; Herceptin, an anti-HER2 antibody; Nutropin Depot growth hormone; Nutropin growth hormone; Protropin growth hormone; Nutropin AQ, a liquid formulation growth hormone; TNKase, a thrombolytic agent; Activase, a tissue plasminogen activator; Cathflo Activase; Pulmozyme, an inhalation solution; Xolair, an anti-IgE antibody; Raptiva, an anti-CD11a antibody; and Avastin, a humanized antibody. It also licenses various additional products to other companies. Genentech's products under development cover various medical conditions, including cancer, respiratory disorders, cardiovascular diseases, endocrine disorders, and inflammatory and immune problems. In addition, the company, jointly with Rinat Neuroscience Corp., develops RI 624, a humanized monoclonal antibody that blocks nerve growth factor. Genentech has collaboration agreements with Array Biopharma, Inc. and Curis, Inc. for the discovery of targeted small-molecule drugs for the treatment of cancer; with Accelerate Brain Cancer Cure relating to Avastin in patients with glioblastoma multiforme, a form of brain cancer; with PIramed, Ltd. to develop anti-cancer drugs; and with Lexicon Genetics, Inc. to discover and develop biotherapeutic drugs. The company's products are sold primarily to wholesalers, specialty distributors, or directly to hospital pharmacies. Genentech was founded by Robert A. Swanson and Herbert W. Boyer in 1975. The company is headquartered in South San Francisco, California.
GLAXOSMITHKLINE PLC (GSK)
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products worldwide. The company operates in two segments, Pharmaceuticals and Consumer Healthcare. The Pharmaceutical segment offers prescription pharmaceuticals and vaccines. Its primary pharmaceutical products include medicines in nine therapeutic areas, including central nervous system, respiratory, anti-virals, anti-bacterials, vaccines, oncology and emesis, metabolic, cardiovascular, and urogenital. The Consumer Healthcare segment provides various over-the-counter medicines, oral care, and nutritional healthcare products. Its oral care products include toothpastes and mouthwashes, toothbrushes, and denture care products. Its nutritional healthcare products include glucose energy and sports drinks, a blackcurrant juice-based drink with vitamin C, and a range of milk-based malted food and chocolate drinks. GlaxoSmithKline has a strategic alliance with Theravance, Inc. to develop and commercialise medicines across a various therapeutic areas; Cytokinetics, Inc. to discover, develop, and commercialize small molecule drugs targeting kinesin spindle protein and certain other cytoskeletal proteins involved in cell proliferation for applications in the treatment of cancer and other diseases; and a partnership with Aeras Global TB Vaccine Foundation to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A. The company was founded in 1935 and is headquartered in London.
Alkermes, Inc. develops pharmaceutical products based on drug delivery technologies. The company's commercial product, Risperdal Consta, is an antipsychotic medication approved for use in schizophrenia and is marketed worldwide. Its product candidate under development, Vivitrex, is a once-a-month injection for the treatment of alcohol and opioid dependence. The company has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technologies, ProLease and Medisorb, as well as inhaled drug products based on AIR technology. The company has collaborations with Cephalon, Inc., Janssen-Cilag, Eli Lilly and Company, Serono S.A., and Amylin Pharmaceutical, Inc. Alkermes was founded in 1987 and is headquartered in Cambridge, Massachusetts.
IMCLONE SYSTEMS INCORPORATED (IMCL)
ImClone Systems Incorporated, a biopharmaceutical company, engages in developing and commercializing biologic medicines in the area of oncology in the United States. Its research and development programs include growth factor blockers and angiogenesis inhibitors. The company's primary product, ERBITUX, is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and inhibits the binding of epidermal growth factor and other ligands, such as transforming growth factor-alpha. The company also conducts registration studies evaluating ERBITUX for the treatment of colorectal, head and neck, lung, and pancreatic cancers, as well as other indications. In addition, it develops cancer vaccines, as well as investigational inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. ImClone Systems has collaboration agreements with Bristol-Myers Squibb Company for developing and promoting ERBITUX in the United States, Canada, and Japan; and with Merck KGaA for the development and commercialization of the recombinant gp75 antigen product candidate and ERBITUX. The company was founded in 1984 and is headquartered in New York City.
AMYLIN PHARMACEUTICALS INC (AMLN)
Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.
DENDREON CORPORATION (DNDN)
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.
GENTA INCORPORATED (GNTA)
Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases in the United States. Its research portfolio comprises two primary areas, DNA/RNA medicines, which include drugs that are based on chemical modifications of oligonucleotides; and small molecules. The company's lead product from the DNA/RNA medicines program is Genasense, which completed phase 3 trials in combination with chemotherapy in the treatment of malignant melanoma, chronic lymphocytic leukemia, multiple myeloma, nonsmall cell lung cancer, small cell lung cancer, and prostate cancer. Genasense inhibits production of Bcl-2, a protein made by cancer cells that is designed to block chemotherapy-induced apoptosis. Its lead product from small molecule program is Ganite, which is used for treatment of cancer-related hypercalcemia that is resistant to hydration. Genta's preclinical pipeline includes research programs in antisense, RNA interference, and decoys. In addition, the company is evaluating oral formulations of gallium-containing compounds. Genta was founded in 1988 and is based in Berkeley Heights, New Jersey.
VION PHARMACEUTICALS INC (VION)
Vion Pharmaceuticals, Inc., a development stage company, engages in the development of therapeutics for the treatment of cancer. The company has two small molecule anticancer agents, including CLORETAZINETM (VNP40101M) and Triapine, in clinical development; and other small molecules and a drug delivery system, including KS119W and heterocyclic hydrazones in preclinical development. Its lead product candidate CLORETAZINETM (VNP40101M), which is in Phase II single agent trial, is a sulfonylhydrazine alkylating agent for the treatment of relapsed acute myelogenous leukemia. Triapine is a small molecule that inhibits the enzyme ribonucleotide reductase, and prevents the replication of tumor cells by blocking a critical step in DNA synthesis. Triapine is in Phase II combination trial with gemcitabine in pancreatic cancer. KS119 is an additional cytotoxic (cell-damaging) compound from the sulfonylhydrazine class. Heterocyclic hydrazones are anticancer compounds that have demonstrated potent antitumor effects. It also has one product development program, TAPET (Tumor Amplified Protein Expression Therapy), a drug delivery system using modified Salmonella bacteria, which is designed to deliver anticancer agents directly to solid tumors. Vion Pharmaceuticals has a collaboration agreement with the National Cancer Institute for the clinical development of Triapine. The company was incorporated in 1992 and was formerly known as OncoRx, Inc. It changed its name to Vion Pharmaceuticals, Inc. in 1996. Vion Pharmaceuticals is based in New Haven, Connecticut.
AstraZeneca PLC, a pharmaceutical company, engages in the research, development, manufacture, and marketing of prescription pharmaceuticals, as well as the supply of healthcare services worldwide. It provides medicines designed to fight disease in areas of medical need, such as cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory. The company's product portfolio includes Casodex, Arimidex, and Faslodex for treating cancer; disease Nexium for gastrointestinal problems; Symbicort for asthma; Atacand for treating hypertension; Crestor for treating high cholesterol; Zomig for treating migraine; and Seroquel for treating schizophrenia. AstraZeneca has strategic alliance with Cambridge Antibody Technology (CAT) for discovering and developing human antibody therapeutics in inflammatory disorders. In addition, it also engages in research and development, manufacture, and marketing of medical devices and implants for use in healthcare. AstraZeneca has a collaboration agreement with Caprion Pharmaceuticals, Inc. focused on the discovery of targets for the treatment of prostate cancer; with Avanir Pharmaceuticals to evaluate the human safety of AZD2479, a compound under development as reverse cholesterol transport enhancer; with University of Texas MD Anderson Cancer Center for integrated preclinical and clinical research on new treatments for cancer, focusing initially on aerodigestive diseases; and with Targacept, Inc. to develop and commercialize Targacept's phase II compound TC-1734 to treat Alzheimer's disease and schizophrenia. The company was incorporated in 1992 and was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999. AstraZeneca PLC is headquartered in London.
Cell Genesys, Inc., a biotechnology company, engages in the research, development, and commercialization of biological therapies for patients with cancer. The company develops cell-based cancer vaccines, oncolytic virus therapies, and antiangiogenesis therapies to treat various types of cancer. Its clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified during product development to impart disease-fighting characteristics. The company's clinical-stage programs include GVAX cancer vaccines and oncolytic virus therapies. Cell Genesys' GVAX cancer vaccines program includes Phase 3 clinical trials for prostate cancer and Phase 2 clinical trials for pancreatic cancer and leukemia. The company's oncolytic virus therapies program includes a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer and other types of cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Abgenix, Inc. Cell Genesys was incorporated in 1988 and is headquartered in South San Francisco, California.
INCYTE CORPORATION (INCY)
Incyte Corporation engages in the discovery and development of small molecule drugs to treat medical conditions, including the infection with human immunodeficiency virus (HIV), inflammatory disorders, cancer, and diabetes. Its primary product candidate Reverset is a nucleoside analog reverse transcriptase inhibitor for use in combination with other antiviral drugs for patients with HIV infections, and is in phase IIb clinical trials. In addition, the company's drug discovery programs underway include CCR2 Receptor Antagonist Program and Sheddase Inhibitor Program. CCR2 Receptor Antagonist Program is focused on developing antagonists to a key chemokine receptor involved in inflammation called CCR2. CCR2 is a chemokine receptor found on monocytes that controls their migration into sites of inflammation. The primary products candidate form this program is in phase IIa clinical trial in patients with rheumatoid arthritis. The Sheddase Inhibitor Program involves sheddase inhibitors that would have application in the treatment of breast cancer and other tumor types and is in phase I clinical trials. The company markets its products in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. Incyte has collaborative agreement with Pharmasset, Inc.; Senomyx, Inc.; Genomic Health, Inc.; Pfizer, Inc.; and Medarex, Inc. Incyte was founded in 1991 and is headquartered in Wilmington, Delaware.
Medarex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of human antibody-based therapeutic products. The company's UltiMAb human antibody development system enables to create and develop antibodies products for a range of diseases, including cancer and rheumatoid arthritis, as well as for other inflammatory, autoimmune, and infectious diseases. As of March 31, 2005, the company had 22 antibody product candidates generated from its UltiMAb Human Antibody Development System that were in human clinical trials for the treatment of a range of diseases. In addition, its preclinical and clinical development of therapeutic antibody products pipeline include product candidates MDX-010, which is developing jointly with Bristol-Myers Squibb Company, for the treatment of metastatic melanoma and other cancers; MDX-060 for lymphomas; MDX-070 for prostate cancer; MDX-214 for cancer; and MDX-1307 for genitourinary and breast cancers. Further, the company is developing MDX-066, jointly with The Massachusetts Biologic Laboratories of the University of Massachusetts Medical School, for the treatment of Clostridium difficile associated diarrhea; as well as MDX-018, jointly developing with Genmab A/S for autoimmune disease. As of March 1, 2005, Medarex had approximately 50 partnerships with pharmaceutical and biotechnology companies to jointly develop and commercialize products or to enable other companies to use its proprietary technology in their development of new therapeutic products. The company also has a strategic alliance agreement with Devon Health Services, Inc. to form a clinical trials organization. Medarex was founded in 1987 and is headquartered in Princeton, New Jersey.
NexMed, Inc., a pharmaceutical and medical technology company, engages in the design, development, manufacture, and commercialization of therapeutic products based on proprietary delivery systems. It develops transdermal treatments based on the NexACT drug delivery technology, which might enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed for the absorption of an active drug through the skin and enabling high concentrations of the active drug to penetrate the desired site of the skin or extremity. The company's primary NexACT product under development is the Alprox-TD cream treatment for erectile dysfunction. NexMed also develops Femprox an alprostadil-based cream product intended for the treatment of female sexual arousal disorder; NM100060 nail lacquer topical solution; NM100061 early ejaculation cream; NM100064 arthritic pain patch; NM100065 anti-emetic patch; and NM100080 wound healing/decubitus ulcers cream. The company operates in the United States and Hong Kong. NexMed was incorporated in 1987 and is based in Robbinsville, New Jersey.
INVITROGEN CORPORATION (IVGN)
Invitrogen Corporation provides products and services that support academic and government research institutions, and pharmaceutical and biotech companies in the United States and Europe. It operates in two segments, BioDiscovery and BioProduction. BioDiscovery segment includes functional genomics, cell biology, and drug discovery product lines. This segment also comprises a range of enzymes, nucleic acids, and other biochemicals and reagents. The company also offers software through this segment that enables analysis and interpretation of genomic, proteomic, and other biomolecular data for application in pharmaceutical, therapeutic, and diagnostic development. BioProduction segment includes various cell culture products and biological testing services. Its products comprise sera, cell, and tissue culture media; reagents used in both life sciences research and in processes to grow cells in the laboratory and to produce pharmaceuticals; and other materials made through cultured cells. BioProduction's services include testing to ensure that biologics are free of disease-causing agents or do not cause adverse effects; characterization of products' chemical structures; development of formulations; and validation of purification processes under regulatory guidelines. It also manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. The company serves the life sciences research market; biotechnology, pharmaceutical, energy, agricultural, and chemical companies; and industries that apply genetic engineering to the commercial production. It supplies its products through its own sales force and agents or distributors. Invitrogen has collaboration with Families of Spinal Muscular Atrophy to identify biological targets that are linked to the causes and symptoms of spinal muscular atrophy. The company was founded in 1987 and is headquartered in Carlsbad, California.
MYRIAD GENETICS INC (MYGN)
Myriad Genetics, Inc., a biopharmaceutical company, engages in the development and marketing of therapeutic and molecular diagnostic products. Its lead drug candidate is Flurizan, a therapeutic drug for the treatment of Alzheimer's disease, which completed a Phase II human clinical trial in patients with mild to moderate Alzheimer's disease. Flurizan is also in a Phase IIb human clinical trial for the treatment of patients with premetastatic prostate cancer. The company's other products under development include MPC-6827, a small-molecule drug candidate that inhibits tubulin, an important protein involved in cell division for treatment of advanced solid tumors or metastatic brain tumors; MPC-2130, a novel apoptosis inducing small molecule for the treatment of metastatic tumors or blood cancers, as well as refractory cancer, ovarian cancer, and prostate cancer; and MPI-49839, a viral budding inhibitor for the treatment of AIDS. It also offers various predictive medicine products, including BRACAnalysis, which assesses a woman's risk of developing breast and ovarian cancer; COLARIS and COLARIS AP, which determine a person's risk of developing colon cancer; and MELARIS, which assesses a person's risk of developing malignant melanoma. Myriad Genetics has strategic alliances with Abbott Laboratories and E.I. du Pont de Nemours and Company. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.
PDL BioPharma, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions, and cancer. It markets and distributes various biopharmaceutical products, including Cardene I.V. for the short-term treatment of hypertension; Retavase, a fibrinolytic agent for the management of acute myocardial infarction or heart attack in adults for the improvement of ventricular function; and IV Busulfex that is used as a conditioning agent in blood or marrow transplantation in chronic myelogenous leukemia. The company also develops various other products, such as Daclizumab for the treatment of asthma and multiple Sclerosis; Ularitide to treat decompensated congestive heart failure; Terlipressin for the treatment of Type 1 hepatorenal syndrome; HuZAF to treat crohn's disease; Nuvion for the treatment of severe steroid-refractory ulcerative colitis; and M200 to treat solid tumors. PDL BioPharma markets its biopharmaceutical products in the United States and Canada through its hospital sales force. The company was founded by Laurence Jay Korn in 1986. It was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in June 2005. PDL BioPharma is headquartered in Fremont, California.
Allergan, Inc. engages in the development and commercialization of pharmaceutical products for the ophthalmic, neurological, dermatological, and other markets. It engages in pharmaceutical research related to disease areas, such as glaucoma, retinal disease, dry eye, psoriasis, acne, and movement disorders. The company also offers aesthetic-related pharmaceuticals and over-the-counter products. Allergan offers prescription and nonprescription products to treat diseases and disorders of the eye, including glaucoma, dry eye, inflammation, infection, and allergy. Its glaucoma treatment products include Alphagan and Alphagan P, a brimonidine tartrate ophthalmic solution; Lumigan, a bimatoprost ophthalmic solution; and Restasis, a cyclosporine ophthalmic emulsion. Its ophthalmic anti-inflammatory products include Acular and Acular LS, as well as Pred Forte, a topical steroid. The company's ophthalmic infection treatment products include Ocuflox, Oflox, Zymar, and Exocin. It offers Alocril and Elestat ophthalmic solutions for the treatment of itch associated with allergic conjunctivitis. The company's neuromodulator product, Botox, is used therapeutically in the treatment of neuromuscular disorders. Allergan's skin care products include Tazorac gel for the treatment of plaque psoriasis; Azelex cream used in the topical treatment of mild to moderate inflammatory acne; Avage, a tazarotene cream indicated for the treatment of facial fine wrinkling, mottled hypo and hyperpigmentation, and benign facial lentigines; Prevagetm, an antioxidant cream, that reduces the appearance of fine lines and wrinkles, as well as provides protection against sun damage, air pollution, and cigarette smoke; and glycolic acid-based products. Allegran, Inc. has a strategic research collaboration agreement with ExonHit Therapeutics to identify new molecular targets based on ExonHits' gene profiling DATAS technology. Allegran was incorporated in 1948 and is headquartered in Irvine, California.
PENWEST PHARMACEUTICALS CO (PPCO)
Penwest Pharmaceuticals Co. develops pharmaceutical products based on proprietary oral drug delivery technologies primarily in North America and Europe. The company is developing two drug development pipelines, which include oxymorphone ER, an extended release formulation of oxymorphone, a narcotic analgesic being developed for twice-a-day dosing in patients with moderate to severe pain requiring opioid therapy for an extended period of time; and PW2101, a beta blocker intended for the treatment of hypertension and angina. Its drug delivery technologies include TIMERx, an extended release delivery system that is adaptable to soluble and insoluble drugs, as well as flexible for a various controlled release profiles; Geminex, a dual drug delivery system to provide independent release of different active ingredients contained in a drug; SyncroDose, a drug delivery system to release the active ingredient of a drug at the desired site and time in the digestive tract; and Gastroretentive system, a drug delivery system to provide controlled release delivery of drugs that are absorbed in the stomach and upper portions of the GI tract, without a loss of bioavailability. Penwest Pharmaceuticals is also developing various additional product candidates in areas, such as edema, epilepsy, schizophrenia, and depression. The company has a collaboration agreement with Endo Pharmaceuticals, Inc. for the development of oxymorphone ER product. Penwest Pharmaceuticals is headquartered in Danbury, Connecticut.
Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of products to treat sleep disorders, neurological disorders, cancer, and pain primarily in the United States. The company, through its wholly-owned subsidiary, CIMA LABS INC., also develops and manufactures orally disintegrating tablets using proprietary technologies. It markets three proprietary products, including Provigil for treating of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder; Actiq for treating pain in opiod-tolerant cancer patients; and Gabitril, which is used as an adjunct therapy for treatment of partial seizures associated with epilepsy. The company sells its products primarily in North America and Europe. Cephalon has an agreement with Bio3 Research and Creabilis to develop K 252a-based products as topical therapies for psoriasis and for the treatment and prevention of restenosis. The company was founded by Frank Baldino, Jr. and is headquartered in West Chester, Pennsylvania.
Immunomedics, Inc. engages in the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune, and other diseases. The company offers its CEA-Scan, a diagnostic imaging agent used for the detection of colorectal cancers, in the United States and Canada, as well as in Europe. It offers its LeukoScan, a diagnostic product used for the detection of bone infections, in Europe and Australia. Immunomedics' therapeutic product candidates primarily comprised epratuzumab, which completed certain Phase II clinical trials for the treatment of nonHodgkin's lymphoma, as well as labetuzumab, which was in Phase I/II clinical trials for the treatment of certain solid tumors and hematologic malignancies, as of June 30, 2004. The company was founded by David M. Goldenberg. Immunomedics was incorporated in 1982 and is headquartered in Morris Plains, New Jersey.
Affymetrix, Inc. engages in the development, manufacture, sale, and service of systems for genetic analysis for use in the life sciences and in clinical diagnostics. The company's GeneChip system consists of components, including disposable probe arrays containing genetic information on a chip, reagents for extracting, amplifying, and labeling target nucleic acids, a fluidics station for introducing the test sample to the probe arrays, a hybridization oven for optimizing the binding of samples to the probe arrays, a scanner to read the fluorescent image from the probe arrays, and software to analyze and manage the resulting genetic information. The company also offers related microarray technology, which includes instrumentation, software, and licenses for fabricating, scanning, collecting, and analyzing results from low density microarrays. It sells its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe. Affymetrix has an agreement with The Jeffrey Modell Foundation and National Human Genome Research Institute to develop two molecular DNA tests that could help save the lives of children born with severe combined immunodeficiency and other primary immunodeficiency disorders; a collaboration with CureSearch Children's Oncology Group to discover and validate gene expression signatures, or genetic fingerprints, for various common childhood cancers, including leukemia and sarcoma, a common solid tumor; and a collaboration with Imperial College London and the Medical Research Council to discover the genetic variations associated with cancer, cardiovascular disease, and diabetes. The company was founded in 1991 and is headquartered in Santa Clara, California.
AASTROM BIOSCIENCES INC (ASTM)
Aastrom Biosciences, Inc., a development stage company, develops patient-specific products for the repair or regeneration of human tissues, utilizing its proprietary adult stem cell technology. Its lead products include tissue repair cells (TRCs), which are a mixture of bone marrow-derived adult stem and progenitor cells, produced outside of the body or ex vivo' from a small amount of bone marrow taken from the patient. The company also offers AastromReplicell System, a patented, integrated system of instrumentation and single-use consumable kits for the commercial production of human cells. Aastrom Biosciences is developing TRCs for the treatment of severe bone fractures, ischemic vascular disease, jaw reconstruction, and spine fusion. It also focuses on the utilization of TRCs in the areas of bone regeneration and vascular regeneration in limb ischemia resulting from diabetes and other diseases. The company has a strategic alliance with Musculoskeletal Transplant Foundation to develop and commercialize treatments for the regeneration of tissues, such as bone and cartilage. Aastrom Biosciences was incorporated in 1989 and is headquartered in Ann Arbor, Michigan.
PEREGRINE PHARMACEUTICALS INC (PPHM)
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for the treatment of cancer, viruses, and other diseases using targeted antibodies. The company's products portfolio includes Cotara for brain cancer, which is in Phase II/III registration trial, and Tarvacin, an anti-phospholipid therapy agent for the treatment of solid tumors and chronic hepatitis C virus infection. Its vascular research programs fall under various technology platforms, including tumor necrosis therapy, antiphospholipid therapy, vascular targeting agents, antiangiogenesis, and vasopermeation enhancement agent technology. In addition, the company, through its wholly owned subsidiary, Avid Bioservices, Inc., provides a range of contract manufacturing services, including contract manufacturing of antibodies and proteins, cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies. The company was founded in 1981 as Techniclone International Corporation. It changed its name to Techniclone Corporation in 1997 and to Peregrine Pharmaceuticals, Inc. in 2000. Peregrine Pharmaceuticals is based in Tustin, California.
ALEXION PHARMACEUTICALS INC (ALXN)
Alexion Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of biologic therapeutic products for the treatment of severe diseases. It develops therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases, and cancer; and additional antibody therapeutics for other medical needs. The company primarily develops two lead product candidates, eculizumab and pexelizumab, which address specific diseases that arise when the human immune system produces inflammation in the human body. Eculizumab is in phase III clinical development for treatment of Paroxysmal Nocturnal Hemoglobinuria, a chronic hematologic disease. Pexelizumab is in clinical development for the reduction of the incidence of death, myocardial infarction or heart attack, and other complications associated with coronary artery bypass graft surgery; and for acute myocardial infarction. Alexion Pharmaceuticals has a strategic alliance with Procter and Gamble Pharmaceuticals for the development of pexelizumab. The company was co-founded by Leonard Bell, Stephen P. Squinto, Scott A. Rollins, and Joseph A. Madri in 1992. Alexion Pharmaceuticals is headquartered in Cheshire, Connecticut.
The Medicines Company, a pharmaceutical company, engages in the acquisition, development, and commercialization of acute care hospital products. The company offers Angiomax, a direct thrombin inhibitor, for use as an anticoagulant in patients with unstable angina undergoing coronary angioplasty. It also develops clevelox, an intravenous drug intended for the short-term control of blood pressure in surgical patients, including patients undergoing cardiac surgery; and cangrelor, an antiplatelet agent that prevents platelet aggregation. The company markets, distributes, and sells its products to hospital management, physicians, hospital pharmacists, nurses, and other care staff in the United States, as well as through third-party distributors internationally. It has licensing agreements with Biogen Idec, Inc. and AstraZeneca AB. The company was founded in 1996 and is headquartered in Parsippany, New Jersey.
ARENA PHARMACEUTICALS INC (ARNA)
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs in the therapeutic areas of metabolic, cardiovascular, inflammatory, and central nervous system diseases. The company is developing a pipeline of compounds that act on drug targets called G protein-coupled receptors, using its proprietary technologies, including Constitutively Activated Receptor Technology and Melanophore. Arena's products principally include APD356, a Phase II clinical trial 5-HT2C serotonin receptor agonist, which would be used for the treatment of obesity; and APD125, a Phase I clinical trial product, for the treatment of insomnia. Arena Pharmaceuticals has research collaborations with Ortho-McNeil Pharmaceutical, Inc. and Merck & Co., Inc. for products in various indications. The company was co-founded by Dominic P. Behan and Jack Lief. Arena Pharmaceuticals was incorporated in 1997 and is based in San Diego, California.
ISIS PHARMACEUTICALS INC (ISIS)
Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs to treat various therapeutic areas, including inflammatory, metabolic, and cardiovascular diseases, as well as cancer. The company operates through two segments, Drug Discovery and Development, and Ibis. The Drug Discovery and Development segment develops antisense inhibitors through its proprietary technology. The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients in the United States and Europe. It also develops new formulations of antisense drugs, such as oral, topical cream, subcutaneous, intravitreal, aerosol, and enema. The company's drugs under development include Alicaforsen for Ulcerative Colitis in Phase II clinical trial and ISIS 113715 for diabetes in Phase II clinical trial. In addition, it develops second-generation inhibitors, such as apoB-100 for the lowering of cholesterol and ISIS 301012, a Phase I study of an oral capsule formulation. The Ibis segment offers Triangulation Identification for Genetic Evaluation of Risks (TIGER) technology, a biosensor system, for identification of infectious diseases. TIGER biosensor system identifies various bacteria and viruses in both environmental and human clinical samples and used for epidemiological surveillance, biological products screening, and microbial forensics applications. The company has strategic alliance and collaboration agreements with Novartis Ophthalmics AG; Ercole Biotech, Inc.; Alnylam Pharmaceuticals, Inc.; OncoGenex Technologies, Inc.; Santaris Pharma A/S; Eli Lilly and Company; Antisense Therapeutics, Ltd.; and Sarissa, Inc. Isis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California.
UNITED THERAPEUTICS CORPORATION (UTHR)
United Therapeutics Corporation (UTC), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular, cancer, and infectious diseases. The company's primary product, Remodulin, an injection for the treatment of pulmonary arterial hypertension in patients with NYHA class II-IV symptoms to diminish symptoms associated with exercise. UTC also develops four therapeutic platforms: immunotherapeutic monoclonal antibodies, which are antibodies that activate patients' immune systems to treat cancer, including OvaRex, which would be used for the treatment of metastatic ovarian cancer; glycobiology antiviral agents that are small molecules and would be used as an oral therapy for hepatitis C and other infections; telemedicine, which includes sportable digital devices that enable physicians to remotely monitor patients' bodily measurements such as heart function, including the CardioPAL family of cardiac event recorders and the Decipher Holter monitors; and arginine formulations, including the HeartBar and other products, which deliver the amino acid arginine that is necessary for maintaining vascular function. The company was founded in 1996 as Lung Rx, Inc. and changed its name to United Therapeutics Corporation in 1997. UTC was founded by Martine Rothblatt. United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
CV THERAPEUTICS INC (CVTX)
CV Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases. Its lead clinical development product includes Ranexa, which would be used for the treatment of chronic angina, a debilitating heart condition. The company also develops Regadenoson, a Phase III clinical trial product, an A2A-adenosine receptor agonist for use as a pharmacologic agent in cardiac perfusion imaging studies; Tecadenoson, a Phase III clinical trial product, an A1-adenosine receptor agonist for the reduction of rapid heart rate during atrial arrhythmias; and Adentri, a Phase II clinical trial product, an A1-adenosine receptor antagonist for the treatment of congestive heart failure. It also has various products in the pre-clinical stage development. It has collaboration agreement with Biogen, Inc. and Fujisawa Healthcare, Inc. In addition, the company is co-promoting ACEON tablets, an angiotensin converting enzyme inhibitor, with its collaborative partner, Solvay Pharmaceuticals, Inc. CV Therapeutics was founded in 1990 and is headquartered in Palo Alto, California.
CUBIST PHARMACEUTICALS INC (CBST)
Cubist Pharmaceuticals, Inc. engages in the research, development, and commercialization of products for anti-infective and acute care needs market. Its principal product, Cubicin, is approved in the United States for the treatment of skin and skin structure infections caused by certain gram-positive bacteria. The company's pipeline includes HepeX-B, a monoclonal antibody biologic that is in second of two Phase 2 trials, for the prevention of infection by Hepatitis B virus in liver transplant patients, as well as research efforts focused on members of the lipopeptide class of molecules. Cubist has a licensing agreement with XTL Biopharmaceuticals, Ltd., for the development and commercialization of HepeX-B. The company was founded in 1992 and is headquartered in Lexington, Massachusetts.
ENDO PHARMACEUTICALS HOLDINGS INC (ENDP)
Endo Pharmaceuticals Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Through its wholly owned subsidiary, Endo Pharmaceuticals, Inc., it engages in the research, development, marketing, and sale of branded and generic pharmaceutical products primarily used to treat and manage pain. The company's branded products include Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. Lidoderm is a topical patch product containing lidocaine for the relief of the pain from post-herpetic neuralgia. Percocet and Percodan are used for the treatment of moderate-to-severe pain. Frova used for prevention of menstrually related migraine. DepoDur used for the treatment of pain following major surgery. Zydone tablets are also used for the relief of moderate-to-severe pain and contain hydrocodone/acetaminophen. The company's generic products comprise morphine sulfate, generic oxycodone hydrochloride, and acetaminophen product, which focus on pain management. Endo Pharmaceuticals also offers carbidopa/levodopa, the generic version of Sinemet for the treatment of the symptoms of idiopathic Parkinson's disease. In addition, the company is developing products for the acute, chronic, and neuropathic pain conditions, as well as in complementary therapeutic areas. It sells its products to pharmacy chains and wholesale drug distributors who supply to pharmacies, hospitals, governmental agencies, and physicians. The company has a strategic alliance with SkyePharma, Inc. Endo was incorporated in 1997 and is headquartered in Chadds Ford, Pennsylvania.
INSPIRE PHARMACEUTICALS INC (ISPH)
Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovery, development, and commercialization of prescription pharmaceutical products in the ophthalmic and respiratory therapeutic areas. It has product candidates in various stages of clinical development and various programs in preclinical development. The company's clinical product candidates are based on proprietary technology relating to P2 receptors. Its products in clinical development include INS365 Ophthalmic for treating dry eye disease and corneal wound healing; INS37217 Respiratory for the treatment of cystic fibrosis; INS37217 Ophthalmic for the treatment of retinal disease; and INS50589 Antiplatelet for use in acute cardiac care. In addition, the company has rights to co-promote Elestat, for the treatment of allergic conjunctivitis; and Restasis, for the treatment of dry eye disease in the United States under collaborative agreements with Allergan, Inc. It also has collaborative partnerships with Santen Pharmaceutical Co., Ltd., and Cystic Fibrosis Foundation Therapeutics, Inc., as well as license agreements with the University of North Carolina at Chapel Hill and Wisconsin Alumni Research Foundation. The company was incorporated in 1993 and is based in Durham, North Carolina.
BIOVAIL CORPORATION (BVF)
Biovail Corporation engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing oral drug-delivery technologies primarily in North America. Its primary focus is on various therapeutic areas, including cardiovascular disease, central nervous system disorders, and pain management. The company's portfolio of oral drug-delivery technologies include controlled release, graded release, enhanced absorption, rapid absorption, taste masking, and oral disintegration. Biovail's products are commercialized in various countries through licensing agreements with strategic marketing partners. In addition, the company promotes and/or co-promotes products on behalf of third parties; provides research, development, and clinical contract research services to third parties; and sells its controlled release products through third parties. Biovail was founded in 1983 and is headquartered in Mississauga, Canada.
MGI Pharma, INC., a biopharmaceutical company, engages in the acquisition, development, and commercialization of proprietary pharmaceutical products for the needs of cancer patients. The company's product portfolio includes, Aloxi (palonosetron hydrochloride) injection for the prevention of chemotherapy-induced nausea and vomiting; Salagen tablets (pilocarpine hydrochloride) for the symptoms of radiation-induced dry mouth in head and neck cancer patients, as well as to rheumatologists as a treatment for dry mouth associated with the autoimmune disease Sjögren's syndrome; Hexalen (altretamine) capsules, which is an orally administered chemotherapeutic agent for ovarian cancer patients; and Kadian (morphine sulfate sustained release) capsules for moderate to severe pain associated with cancer. The company's products in various phases of clinical trials include Dacogen (decitabine) injection for the treatment of patients with myelodysplastic syndrome; Saforis oral suspension for chemotherapy induced inflammation of the tissues lining the mouth, or oral mucositis; ZYC101a for young women with cervical dysplasia; Irofulven for the treatment of prostate, liver, ovarian, and pancreatic tumors; and other acylfulvene analogs. MGI PHARMA markets its products through direct sales force within the United States and through alliances with other pharmaceutical or biotechnology companies in other countries. MGI PHARMA has alliances with Helsinn Healthcare SA; Kissei Pharmaceutical Co., Ltd.; Dainippon Pharmaceutical Co., Ltd.; Pfizer, Inc.; and Novartis Pharma AG. The company was incorporated in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990. MGI PHARMA is headquartered in Bloomington, Minnesota.
CELL THERAPEUTICS INC (CTIC)
Cell Therapeutics, Inc. engages in the discovery, development, acquisition, and commercialization of drugs for the treatment of cancer. The company markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia. Cell Therapeutics develops XYOTAX, paclitaxel linked to a polyglutamate polymer, which is used for the potential treatment of nonsmall cell lung cancer and ovarian cancer. It uses a biodegradable protein polymer to deliver the chemotherapy paclitaxel principally to tumor tissue. The company develops pixantrone, which is in clinical trials for the potential treatment of relapsed aggressive nonhodgkin's lymphoma. It operates primarily in the United States and Italy. The company was co-founded by James A. Bianco, Louis A. Bianco, and Jack W. Singer in 1991. Cell Therapeutics is headquartered in Seattle, Washington.
ANGIOTECH PHARMACEUTICALS INC (ANPI)
Angiotech Pharmaceuticals, Inc. focuses on combining pharmaceutical compounds with medical devices and biomaterials to address common complications associated with certain surgical procedures and processes of various diseases worldwide. It primarily sells coronary stent systems incorporating the drug paclitaxel for the treatment of coronary artery disease. The company's other commercial products include VITAGEL surgical hemostat, a bioresorbable hemostatic material used to reduce patient blood loss during surgical procedures; CoSeal surgical sealant, a biomaterial surgical sealant used to enable tissue repair and regeneration; Collagraft and NeuGraft, collagen-based biomaterial products for orthopaedic and spinal surgery applications; and various polymeric biocompatible coatings for medical devices. Angiotech's ongoing clinical programs include TAXUS Liberte, Vascular Wrap, Adhibit, and Peripheral Drug Eluting Stent Program. TAXUS Liberte is a paclitaxel eluting coronary stent system to treat restenosis, and other local inflammatory and proliferative diseases. Vascular Wrap is used to prevent stenosis following vascular bypass surgery in the limbs. Adhibit adhesion prevention gel, a nondrug-loaded biomaterial product, is undergoing human clinical studies in Europe. Peripheral Drug Eluting Stent Program is a study of a paclitaxel-eluting stent to treat peripheral artery disease in the limbs. In addition, the company has other preclinical programs, including anti-infective central venous catheter program and intra-articular paclitaxel program for the prevention of post injury contractures and cartilage preservation. Angiotech has a strategic alliance with Baxter Healthcare Corporation and CombinatoRx. Angiotech was incorporated in 1989. The company was formerly known as Holwest Industries, Ltd. It changed its name to Angiogenesis Technologies, Inc. in 1992 and to Angiotech Pharmaceuticals, Inc. in 1996. The company is headquartered in Vancouver, Canada.
StemCells, Inc., a biotechnology company, engages in the discovery, development, and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. It develops therapies that use stem and progenitor cells to treat human diseases and injuries, such as neurodegenerative diseases, including Batten's, Parkinson's, and Alzheimer's diseases, and other metabolic genetic disorders. The company also develops its products for demyelinating disorders, including spinal cord injuries, stroke, hepatitis, chronic liver failure, and diabetes; and multiple sclerosis. StemCells is headquartered in Palo Alto, California.
ENZON PHARMACEUTICALS INC (ENZN)
Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.
Geron Corporation, a biopharmaceutical company, engages in the development and commercialization of therapeutic and diagnostic products for cancer based on its telomerase technology, and cell-based therapeutics using its human embryonic stem cell (HESC) technology. The company develops anticancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and, through its licensees, telomerase-based oncolytic (cancer-killing) viruses. It uses HESCs for the manufacture of replacement cells and tissues. It intends to use HESC technology to enable the development of transplantation therapies, facilitate pharmaceutical research and development practices, and for research in human developmental biology. Geron Corporation's nuclear transfer technology is a method for generating whole animals from genetic material derived solely from the nucleus of a single cell obtained from an individual animal. The company was incorporated in 1990 and is headquartered in Menlo Park, California.
Alpharma, Inc., a global specialty pharmaceutical company, engages in the development, manufacture, and marketing of specialty generic human pharmaceutical and animal pharmaceutical products. The company offers a range of generic human pharmaceutical products in tablet, capsule, liquid, and topical formulations and dosage forms. It operates in five segments: Active Pharmaceutical Ingredients (API), Branded Pharmaceuticals (BP), International Generics (IG), U.S. Generic Pharmaceuticals (USG), and Animal Health (AH). The API segment offers a range of antibiotic fermentation based active pharmaceutical ingredients that are used in the manufacture of finished dose pharmaceutical products. The BP segment manufactures, develops, and markets a prescription pain medicine in a capsule dosage form under the trademark Kadian. It also markets a third party's branded prescription product in a tablet dosage form Pexeva. The IG segment offers a range of prescription pharmaceuticals that comprises antibiotic, analgesic/antirheumatic, psychotropic cardiovascular, cough and cold, and corticosteroid therapeutic products; and over-the-counter products that include skin care, gastrointestinal care, and pain relief products for human use. The USG segment provides generic prescription, specialty branded, and over-the-counter pharmaceuticals for human use. The AH segment offers medicated feed additives for food producing animals, such as poultry, cattle, and swine. It sells products primarily to wholesalers, distributors, hospitals, long-term care providers, managed care providers, and mail order companies, as well as merchandising chains in the United States, the United Kingdom, Germany, the Netherlands, Scandinavia, western Europe, Indonesia, China, Asia-pacific, and certain Middle Eastern countries. The company was formed as A.L. Laboratories, Inc. in 1975 and changed its name to Alpharma, Inc. in 1994. Alpharma is headquartered in Fort Lee, New Jersey.
Biomira, Inc., a biotechnology company, engages in the research and development of synthetic vaccines and novel strategies for cancer immunotherapy. The company's product candidates include BLP25 liposome vaccine, a synthetic Mucin 1 peptide vaccine, which is in Phase IIb trial; and Theratope, a carbohydrate vaccine, which is in Phase III trial. It also developed a synthetic MUC 1-based liposomal glycolipopeptide cancer vaccine, BGLP40 liposome vaccine, which in late pre-clinical development, for use in several cancer indications, including ovarian and breast cancer. The company has collaboration agreement with Merck KGaA of Darmstadt for global product development, licensing, and co promotion of BLP25 liposome. Biomira was incorporated in 1985 and is headquartered in Edmonton, Canada.
BIOPURE CORPORATION (BPUR)
Biopure Corporation engages in the development, manufacture, and marketing of pharmaceuticals, called oxygen therapeutics. Its pharmaceuticals are administered intravenously to increase oxygen transport to the body's tissues. The company offers Hemopure for human use, which is approved in South Africa for the treatment of adult surgical patients, who are acutely anemic; for the purpose of eliminating, reducing, or delaying the need for donated red blood cell transfusions in these patients; for the management of patients with cardiovascular ischemia; and as an early intervention in the out-of-hospital setting for the treatment of patients with acute blood loss resulting from traumatic injury. It also offers Oxyglobin to veterinarians for use in the treatment of anemia in dogs in the United States and Europe. The company sells its products through direct sales force and distributors. Biopure was founded in 1984 and is based in Cambridge, Massachusetts.
DR. REDDYS LABORATORIES LTD (RDY)
Dr. Reddy's Laboratories Limited engages in the development, manufacture, and marketing of pharmaceutical products. The company produces finished dosage forms, active pharmaceutical ingredients, diagnostic kits, critical care products, and biotechnology products. It also conducts research in the areas of cancer, diabetes, cardiovascular diseases, inflammation, and bacterial infection. Dr. Reddy's Laboratories sells its products in approximately 100 countries worldwide, including the United States, Russia and other European countries, India, and China. The company has strategic alliances with Par Pharmaceuticals, Inc.; Leiner Health Products, LLC; Cobalt Pharmaceuticals, Inc.; and Pharmascience, Inc. Dr Reddy's Laboratories has a co-development and commercialization agreement with Rheoscience A/S for the joint development and commercialization of balaglitazone (DRF 2593), a partial PPAR gamma agonist, for the treatment of type 2 diabetes. The company was founded by K. Anji Reddy in 1984. Dr. Reddy's Laboratories is headquartered in Hyderabad, India.
SANGAMO BIOSCIENCES INC (SGMO)
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy. The company has strategic partnership with Edwards Lifesciences Corporation. Sangamo BioSciences has a research collaboration agreement with Pfizer, Inc. to develop cell lines for enhanced protein production. Sangamo Biosciences was founded in 1995 by Edward Lanphier. The company is headquartered in Richmond, California.
QLT, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology, dermatology, oncology, and urology primarily in North America. The company's products include Visudyne, which is used for the treatment of choroidal neovascularization; and Eligard products that are used for prostate cancer incorporate a leutinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with its proprietary Atrigel drug delivery system. QLT also offers generic dermatology products, including lidocaine and prilocaine cream, erythromycin and benzoyl peroxide topical gel, mometasone furoate ointment, betamethasone dipropionate cream, and fluticasone propionate cream. In addition, it provides dental products, which include Atridox and Atrisorb-D. The company has strategic alliances with Novartis Ophthalmics. QLT was formed in 1981 and is headquartered in Vancouver, Canada.
Immucor, Inc. engages in the development, manufacture, and marketing of immunological diagnostic medical products primarily in North America and Europe. It offers a line of reagents and automated systems that are used by hospitals, clinical laboratories, and blood banks in various tests performed to detect and identify various properties of cell and serum components of human blood. The company's reagent product lines include ABO blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These reagents are used in tests performed prior to blood transfusion in determining the blood group and type of patients' and donors' blood; detection and identification of blood group antibodies; detection of platelet antibodies; and paternity testing. Immucor's blood bank automation products include ABS2000, an automated blood bank system; ROSYS Plato, a microplate liquid handler and sample processor; DIAS PLUS and GALILEO, which are high volume microplate processors; and Multireader Plus, a spectra photometric microtitration plate reader. These blood bank automation products enable technologist to perform blood compatibility tests. The company also distributes laboratory equipment designed to automate certain blood testing procedures. It sells its products through direct sales personnel, sales agents, and distributors worldwide. Immucor has a joint venture, known as Immucor-Kainos, Inc., with Kainos Laboratories, Inc. for the distribution of its products in Japan; and a development agreement with Inamed Corporation for the production of human collagen mesh. Immucor was founded in 1982 and is headquartered in Norcross, Georgia.
KERYX BIOPHARMACEUTICALS INC (KERX)
Keryx Biopharmaceuticals, Inc., a development stage company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company has two product candidates in the later stages of clinical development, which include sulodexide, or KRX-101, for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes; and perifosine or KRX-0401 for the treatment of multiple forms of cancer. Its other drug portfolio includes three clinical stage oncology compounds, designated as KRX-0402 and KRX-0403. The company has strategic alliances with Alfa Wassermann S.p.A.; Zentaris AG; Opocrin, S.p.A.; Paligent, Inc.; Collaborative Study Group; and Prescient NeuroPharma, Inc. The company was incorporated in 1998 under the name Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999 and to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is headquartered in New York City.
VIROPHARMA INCORPORATED (VPHM)
ViroPharma Incorporated, a pharmaceutical company, engages in the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. It markets and sells Vancocin Pulvules HCl, the oral capsule formulation, in the United States and its territories. Oral Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous and enterocolitis. The company focuses on product development activities on viral diseases, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. Its products under core development program include CMV with an initial focus on CMV infections in recipients of hematopoietic stem cell/bone marrow transplants, and HCV. Noncore development programs target picornaviruses with intranasal pleconaril. The company has strategic relationships with Glaxo SmithKline, Wyeth, Schering-Plough, and Sanofi-Aventis. ViroPharma was incorporated in 1994 and is based in Exton, Pennsylvania.
AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology. Its principal products in development target life-threatening diseases, including cardiovascular disease, infectious disease, and cancer. AVI's lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the re-narrowing of a coronary artery following angioplasty. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting singlestranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease. The company has strategic alliances with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was incorporated in 1980 as Antivirals, Inc. and changed its name to AVI BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.
Dyax Corp. engages in the discovery, development, and commercialization of antibodies, small proteins, and peptides as therapeutic products, particularly in the areas of inflammation and oncology. As of December 31, 2004, the company had two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema and for the prevention of blood loss, and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is conducting an open-label, repeat dose Phase II clinical trial of DX-88. It has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery. The company in collaboration with Debiopharm S.A. for DX-890 has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients. It uses its proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins, and peptides with the potential for the treatment of various diseases. The company has 12 discovery programs underway: 7 in oncology, which are focused on the discovery and development of therapies that fight cancer; 4 focused on targets that are believed to be mediators of inflammation; and 1 program focused on an infectious disease target. The company has collaboration agreements with AstraZeneca AB; Dendreon Corporation; Baxter Healthcare S.A.; Biogen Idec, Inc.; Inhibitex, Inc.; Debiopharm S.A.; and Syntonix Pharmaceuticals, Inc. Dyax was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
REGENERON PHARMACEUTICALS INC (REGN)
Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter & Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.
SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.
ALLOS THERAPEUTICS INC (ALTH)
Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule drugs for cancer treatments. Its three product candidates under development include Efaproxyn, PDX, and RH1. The Efaproxyn is a synthetic small molecule designed to sensitize hypoxic or oxygen-deprived areas of tumors during radiation therapy. It is evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer. PDX is a small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, a folic acid dependent enzyme involved in the building of nucleic acid and other processes. PDX is in a Phase 1/2 single-agent study in patients with nonHodgkin's lymphoma; a Phase 1 combination study with docetaxel in patients with advanced cancer, including nonsmall cell lung cancer (NSCLC); and a Phase 1 single-agent study to determine the maximum tolerated dose of PDX in patients with NSCLC. RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, which is over-expressed in various tumors relative to normal tissue, including lung, colon, breast, and liver tumors. The company was incorporated as HemoTech Sciences, Inc. in 1992 and changed its name to Allos Therapeutics, Inc. in 1994. Allos Therapeutics is headquartered in Westminster, Colorado.
Pain Therapeutics, Inc., a development stage company, engages in the development of drugs for use in pain management, principally in the area of opioid painkillers. The company's clinical pipeline comprises three proprietary drug candidates, which include Oxytrex, an oral opioid painkiller that is in two Phase III clinical trials for the treatment of severe chronic pain; PTI-901, which is in two Phase III clinical trials to treat men and women with irritable bowel syndrome; and Remoxy, an anti-abuse version of long-acting oxycodone that is in one Phase III clinical trial. It has research and collaboration agreement with Durect Corporation. Pain Therapeutics has a strategic alliance with King Pharmaceuticals, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in South San Francisco, California.
Abaxis, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems for use in veterinary or human patient-care setting to provide clinicians with blood constituent measurements. Its primary product is a blood analysis system, consisting of a 6.9 kilogram analyzer and a series of single-use plastic discs, called reagent discs, containing chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system performs multiple routine tests on whole blood, serum, or plasma samples. It markets this system for veterinary use under the VetScan name and in the human medical market under the Piccolo name. Abaxis sells this system either directly or through distributors in North America, Europe, Asia, and Latin America. The company was co-founded by Vladimir E. Ostoich in 1989 and is headquartered in Union City, California.
KENDLE INTERNATIONAL INC (KNDL)
Kendle International Inc., a contract research organization, provides integrated clinical research services worldwide. The company's services comprise clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consultation, and organizational meeting management and publication services on a contract basis to the pharmaceutical and biotechnology industries. It performs drug development process through various information technology platforms, such as proprietary TrialWare software, including TrialWeb. The company provides contract services related to Phase I through IV clinical trials. It primarily operates in North America, Latin America, Europe, Asia, Africa, and Australia. Kendle International was founded by Candace Kendle and Chris Bergen in 1981, and is headquartered in Cincinnati, Ohio.
FLAMEL TECHNOLOGIES S.A (FLML)
Flamel Technologies S.A., a biopharmaceutical company, engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer-based technologies. The company's technology, Micropump, is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, tastemasking, and bioavailability development. Micropump technology has various other features, including a high loading ratio of active ingredient to its polymer coating, thus enabling for conventional size tablets or capsules. Its primary products based on its Micropump technology comprise Genvir, a controlled-release acyclovir for the treatment of genital herpes; Metformin XL, a controlled-release form of Metformin for the treatment of type II diabetes; and Asacard, a controlled-release formulation of aspirin for the treatment of cardiovascular disease. The company's technology also includes Medusa, a nano-particulate technology that delivers therapeutic proteins, peptides, and small molecules. This technology permits the controlled-release of proteins without the denaturation or other effects on such proteins of various other delivery systems. Its application for Medusa technology is Basulin, which is long-acting insulin for the treatment of diabetes. In addition, the company develops a patented biomaterial, ColCys. ColCys has applications in soft tissue surgical adhesives and the prevention of post-surgical adhesions. The company has operations primarily in France and North America. Flamel has partnerships with Merck & Co., Inc.; GlaxoSmithKline plc; Corning, Inc.; and TAP Pharmaceutical Products, Inc. The company was founded by Gerard Soula in 1990. Flamel Technologies is headquartered in Venissieux, France.
InterMune, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies in pulmonology and hepatology. The company markets various products, including Actimmune (interferon gamma-1b) for the treatment of severe osteopetrosis, and chronic granulomatous disease; Infergen (consensus interferon alfacon-1) for the treatment of patients with compensated liver disease with chronic hepatitis C virus infections; and Amphotec (amphotericin B cholesteryl sulfate complex for injection) for the treatment of invasive aspergillosis. In pulmonology area, InterMune develops Actimmune, a second phase III clinical trial, which is used for the treatment of patients with idiopathic pulmonary fibrosis; and interferon gamma-1b under the name Imukin. In hepatology area, it is developing once-daily Infergen in combination with ribavirin therapy for the treatment of patients suffering from chronic HCV infections; Infergen in combination with Actimmune, which is in Phase IIb clinical trial for the treatment of hepatitis C nonresponders; and PEG-Alfacon-1 that completed phase I clinical trial for the treatment of chronic HCV infections. In addition, the company evaluates Actimmune in patients with ovarian cancer in a Phase III trial. InterMune has collaboration and licensing agreements with Boehringer Ingelheim International GmbH; Maxygen Holdings, Ltd.; and Array BioPharma, Inc. The company was incorporated in 1998 and is headquartered in Brisbane, California.
POLYMEDICA CORPORATION (PLMD)
PolyMedica Corporation provides healthcare products and related services, primarily to seniors in the United States. It operates through three segments: Liberty Diabetes, Liberty Respiratory, and Pharmaceuticals. The Liberty Diabetes segment sells diabetes testing supplies and related products to customers suffering from diabetes. The Liberty Respiratory segment sells prescription respiratory medications and supplies to customers suffering from chronic obstructive pulmonary disease and other breathing disorders. The Pharmaceuticals segment sells prescription medications directly to consumers, as well as manufactures and sells prescription urology and suppository, and over-the-counter female urinary discomfort products. Its prescription urology products include urinary analgesics, antispasmodics, local anesthetics, and analgesic suppositories. This segment markets and sells prescription medications primarily to customers of its Liberty Diabetes and Liberty Respiratory segments. The company sells its prescription urology products to drug distributors; and female urinary discomfort products and home medical diagnostic kits to a network of drug store chains, supermarkets, mass merchandisers, and drug distributors. PolyMedica was organized in 1988 and is headquartered in Woburn, Massachusetts.
PALATIN TECHNOLOGIES INC (PTN)
Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of melanocortin (MC)-based therapeutics in the United States. It markets NeutroSpec, a proprietary radiolabeled monoclonal antibody product, for imaging and diagnosing equivocal appendicitis. The company also conducts additional clinical trials with NeutroSpec and evaluating its potential as an imaging agent for osteomyelitis, post-surgical infection, and inflammatory bowel disease. Its PT-141, a clinical development stage nasally-administered peptide, which would be used for the treatment of both male and female sexual dysfunction. In addition, the company has preclinical development programs based on the MC family, which would be used for various therapeutic indications, including obesity and cachexia; and a program for congestive heart failure. The company has a strategic collaboration agreement with Mallinckrodt Imaging for marketing and distributing NeutroSpec; and a collaborative development and marketing agreement with King Pharmaceuticals, Inc., to jointly develop and commercialize PT-141. Palatin Technologies was incorporated in 1986 and is based in Cranbury, New Jersey.
Chattem, Inc. engages in the marketing and manufacture of a portfolio of branded over-the-counter (OTC) healthcare products, toiletries, and dietary supplements. Its products include topical analgesics, medicated skin care products, medicated dandruff shampoos and conditioner, dietary supplements, and other OTC and toiletry products. The company's topical analgesics comprise arthritis pain reliever, such as ICY HOT and ASPERCREME. Its medicated skin care products consist of GOLD BOND medicated skin care powder, cream, lotion, first aid, and foot care products; and PHISODERM medicated acne treatment products and skin cleansers. The company's medicated dandruff shampoos and conditioner are marketed under the brand name, SELSUN BLUE. Chattem's dietary supplements include DEXATRIM, GARLIQUE, and NEW PHASE. Its other OTC and toiletry products comprise PAMPRIN, a menstrual analgesic; HERPECIN-L, a lip care product; BENZODENT, a dental analgesic cream; and toiletries, such as BULLFROG, a line of sun blocks; ULTRASWIM, a chlorine-removing shampoo; and SUN-IN, a hair lightener. Chattem's products are sold primarily through mass merchandisers, independent and chain drug stores, drug wholesalers, and food stores in the United States and in various markets in approximately 80 countries throughout the world. The company was founded by Zeboim Cartter Patten as the Chattanooga Medicine Company in 1879. It changed its name to Chattem Drug and Chemical Company in 1945 and to Chattem, Inc. in 1978. The company is headquartered in Chattanooga, Tennessee.
LIGAND PHARMACEUTICALS INCORPORATED (LGND)
Ligand Pharmaceuticals Incorporated, a biotech company, engages in the discovery and development of drugs in the United States. It has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; and TAP Pharmaceutical Products, Inc. for the treatment of market indications, such as thrombocytopenia, osteoporosis, menopausal symptoms, and frailty. The company's partnered products include Eltrombopag, a small-molecule TPO mimetic for thrombocytopenia, which is in phase III clinical trials; bazedoxifene, a monotherapy for osteoporosis; Aprela, a combination of bazedoxifene with PREMARIN for osteoporosis prevention, and vasomotor symptoms of menopause; and lasofoxifene, for osteoporosis and vaginal atrophy, which is in phase III clinical trials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Nutrition 21, Inc., a nutritional bioscience company, engages in the research, development, and commercialization of chromium-based nutrition products. It develops and markets Chromax chromium picolinate to vitamin and supplement market for both human and animal applications. The company's products are used in the improving the structure or function of the body, and in the prevention and treatment of metabolic diseases, such as diabetes, insulin resistance, obesity, depression, and cardiovascular diseases. The company has a strategic alliance with XLHealth to incorporate Diachrome, a dietary management product for diabetes, into its treatment protocol. Nutrition 21 was incorporated as Applied Microbiology, Inc. in 1983 and is headquartered in Purchase, New York.
NORTHFIELD LABORATORIES INC (NFLD)
Northfield Laboratories, Inc., a development stage company, engages in the research, development, testing, manufacture, marketing, and distribution of hemoglobin-based blood substitute products. It primarily develops PolyHeme, an oxygen-carrying blood substitute for the treatment of urgent life-threatening blood loss in trauma and resultant surgical settings. The PolyHeme is in Phase III clinical trial. The company was founded in 1985 and is based in Evanston, Illinois.
NYMOX PHARMACEUTICAL CORPORATION (NYMX)
Nymox Pharmaceutical Corporation, through its subsidiaries, engages in the research and development of products for the diagnosis and treatment of Alzheimer's disease. The company markets AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease. It also markets NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products. In addition, Nymox develops therapeutics for the treatment of Alzheimer's disease; treatments for benign prostate hyperplasia; and anti-bacterial agents for the treatment of urinary tract and other bacterial infections in humans, including a treatment for E. coli O157:H7 bacterial contamination in meat and other food and drink products. The company was founded by Paul Averback in 1989 and is based in St. Laurent, Canada.
CHARLES RIVER LABORATORIES INTERNATIONAL INC (CRL)
Charles River Laboratories International, Inc. provides research tools and integrated support services that enable the drug discovery and development process. It operates in three segments: Research Models and Services (RMS), Preclinical Services, and Clinical Services. RMS segment produces and sells research models, primarily genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist its customers in screening drug candidates. In addition, RMS offers transgenic services, laboratory services, consulting and staffing services, vaccine support, and in vitro technology services. Preclinical Services segment offers services in the areas, such as general and specialty toxicology, pathology, interventional and surgical, biopharmaceutical, pharmacokinetic and metabolic analysis, and bioanalytical chemistry. Clinical Services segment conducts Phase I clinical trials; and provides Phase II-IV clinical trials management services, which include testing, medical data sciences services, and regulatory support. Charles River Laboratories sells its products and services primarily through its direct sales force supplemented by a network of international distributors in the United States, Europe, and Japan. The company's customer base includes pharmaceutical, biotechnology, and animal health and medical device companies, as well as various government agencies, hospitals, and academic institutions. It operates approximately 100 facilities in 20 countries worldwide. Charles River Laboratories was founded in 1947 and is headquartered in Wilmington, Massachusetts.
IDEXX LABORATORIES INC (IDXX)
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of veterinary, food, and water testing products and related services worldwide. The company operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and the Food Diagnostics Group (FDG). The CAG segment offers single-use, hand-held test kits that allow test results for various companion animal diseases and health conditions. It also provides instrument systems, including blood and urine chemistry analyzer, and hematology analyzers, as well as offers commercial veterinary laboratory and consulting services. The Water segment develops, designs, manufactures, and distributes products to detect contaminants in water. Its Colilert, Colilert-18, and Colisure tests detect coli-forms and E. coli in water. These water tests are used by government laboratories, water utilities, and private certified laboratories. This segment's products also comprise Enterolert, which detects enterococci in drinking and recreational waters; and Quanti-Tray, which provide users measurements of microbial contamination. FDG manufactures and distributes products to detect disease and contaminants in production animals and food. It sells diagnostic tests and related instrumentation and software that are used to detect a range of diseases and to monitor health status in production animals. The production animal products are purchased primarily by government laboratories, and poultry and swine producers. In addition, this segment sells SNAP beta-lactam, which is used in testing antibiotic residue in milk, to milk producers and processors. The company markets, sells, and services its products through its sales force, as well as through independent distributors and resellers. IDEXX was incorporated in 1983 and is based in Westbrook, Maine.
LIFECELL CORPORATION (LIFC)
LifeCell Corporation engages in the development and marketing of human-derived tissue-based products for use in reconstructive, urogynecologic, and orthopedic surgical procedures to repair soft tissue defects. It develops regenerative human tissue matrix, a three-dimensional structure that contains vascular channels, proteins, and growth factor binding sites, which provide a template for the regeneration of normal human tissue. The company offers AlloDerm for plastic reconstructive, general surgical, burn, and periodontal procedures; Repliform for urogynecologic surgical procedures; GraftJacket and GraftJacket Xpress for orthopedic applications and lower extremity wounds; AlloCraft DBM for bone grafting procedures; and Cymetra, a particulate form of AlloDerm suitable for injection. It also distributes cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns. The company has strategic sales and marketing partnership with Boston Scientific Corporation for Repliform; Wright Medical Group, Inc. for GraftJacket and GraftJacket Xpress; Stryker Corporation for AlloCraftDBM; and BioHorizons Implant Systems, Inc. for periodontal applications of AlloDerm. LifeCell was formed in 1986 and is based in Branchburg, New Jersey.
Shire plc, a specialty pharmaceutical company, engages in the development and marketing of products in the areas of central nervous system, gastrointestinal, renal diseases, and human genetic therapies. The company's product portfolio includes ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder; ADEPT for reduction of adhesions following abdominal surgery; AGRYLIN for the treatment of essential thrombocythaemia; CALCICHEW range used in the treatment and prevention of osteoporosis; CARBATROL, indicated for the treatment of epilepsy; DYNEPO for the treatment of anaemia in patients with chronic renal failure; EQUETRO used for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder; and FOSRENOL, indicated to reduce serum phosphate in patients with end-stage renal disease. It also markets PENTASA for the treatment of patients with mild to moderately active ulcerative colitis; PROAMATINE for the treatment of symptomatic orthostatic hypotension; REMINYL XL for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; REPLAGAL, which is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease; SOLARAZE for the treatment of actinic keratosis; 3TC tablets for the treatment of HIV infection; VANIQA used to treat facial hirsutism in women; XAGRID used for the reduction of elevated platelet counts in at-risk essential thrombocythaemia patients; and ZEFFIX, indicated for the treatment of chronic hepatitis B infection. It markets its products through distributors in the United States, Canada, the United Kingdom, Ireland, Germany, France, Spain, Italy, and Singapore. Shire plc was founded by Dennis Stephens, Harry Stratford, Peter Moriarty, and Geoff Hall in 1986. The company was formerly known as Shire Pharmaceuticals Group plc and changed its name to Shire plc in November 2005. Shire plc is headquartered in Basingstoke, the United Kingdom.
NPS PHARMACEUTICALS INC (NPSP)
NPS Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company's product candidates are used primarily for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders. NPS's products include PREOS, Calcilytic Compounds, Cinacalcet HCl, Teduglutide, mGluR5 Antagonists, Isovaleramide, Delucemine, Metabotropic Glutamate Receptors, and Glycine Reuptake Inhibitors. The PREOS and Calcilytic Compounds are in phase III and I stage respectively, which are used for the treatment of osteoporosis. The Cinacalcet HCl is in phase II stage, which is used for Hyperparathyroidism. The Teduglutide is in phase II stage and is used for short bowel syndrome or crohn's disease. The mGluR5 Antagonists is in the preclinical stage, which is for gastroesophageal reflux disease. The Isovaleramide is in phase II stage and is used for migraine. The Delucemine is in phase I stage that is used for depression. The Metabotropic Glutamate Receptors is in preclinical stage, which is used for psychiatric and neurologic disorders and pain. The Glycine Reuptake Inhibitors is in preclinical stage that is used for schizophrenia and dementia. The company has collaborative research, development, or license agreements with Amgen, Inc.; AstraZeneca AB; Janssen Pharmaceutical N.V; GlaxoSmithKline; Kirin Brewery, Ltd.; and Nycomed Danmark ApS. The company was founded in 1986 and is headquartered in Salt Lake City, Utah.
EMISPHERE TECHNOLOGIES INC (EMIS)
Emisphere Technologies, Inc., a biopharmaceutical company, specializes in the oral delivery of therapeutic macromolecules and other compounds. It develops products using eligen, a proprietary oral drug delivery technology, based on the use of synthetic chemical compounds known as EMISPHERE delivery agents that enable the transport of therapeutic macromolecules, which include proteins, peptides, polysaccharides, and charged organics across biological membranes. The company's development stage products include Oral Unfractionated Heparin, a Phase III product, and Oral Low Molecular Weight Heparin, a Phase I product, for use in the cardiovascular therapeutic area; Oral Salmon Calcitonin, a Phase II product, and Oral Recombinant Parathyroid Hormone, a Phase I product, for the treatment of osteoporosis; Partner proprietary small molecule compounds, a Phase I product, which would be used in the treatment of bone-related diseases; and Oral Recombinant Human Growth Hormone, a Phase I product, for the treatment of growth disorders. Its products in Phase I include Oral Insulin and Oral Glucagon-Like Peptides for the treatment of diabetes, and Oral Cromolyn Sodium for the treatment of asthma and allergies; and preclinical stage products consist of Oral Ciliary Neutrophic Growth Factor and Oral PYY for the treatment of obesity, and Oral Anthrax Antigen, which would be used as an anti-infective. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; a license agreement with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, LTD.; and a research and development agreement with the United States Army Medical Research Institute of Infectious Diseases. The company was founded in 1985 as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies is based in Tarrytown, New York.
DURECT CORPORATION (DRRX)
DURECT Corporation develops pharmaceutical systems based on its proprietary drug delivery technology platforms. It has various product candidates under development in the areas of pain, and other chronic diseases and disorders. Its primary product candidates in development include SABER-Bupivacaine, TRANSDUR-Sufentanil, ORADUR- Oxycodone, DURIN-Leuprolide, and CHRONOGESIC. SABER-Bupivacaine, a post-operative pain relief depot product candidate, is a sustained release injectible using DURECT's SABER delivery system to deliver bupivacaine. TRANSDUR-Sufentanil, a transdermal sufentanil product candidate in phase II clinical studies, uses the TRANSDUR delivery system to deliver sufentanil, an opioid medication, to provide chronic pain relief for up to seven days. ORADUR- Oxycodone, an oral opioid product in phase III clinical studies, would be used to decrease the potential for oxycodone abuse. DURIN-Leuprolide is a product candidate using the DURIN implant system to deliver the peptide leuprolide to treat Alzheimer's disease. The CHRONOGESIC Pain Therapy System is an osmotic implant that would deliver sufentanil for an extended duration. CHRONOGESIC would be used to treat chronic pain and is based on the DUROS System, an osmotic pump. DURECT also engages in the research and development pharmaceutical systems in various therapeutic areas, including chronic pain, central nervous system disorders, and cardiovascular disease. In addition, the company manufactures and sells osmotic pumps used for animal research, and various biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. DURECT has strategic partnerships with Pain Therapeutics, Inc.; Voyager Pharmaceutical Corporation; Endo Pharmaceuticals, Inc.; Endo Pharmaceuticals, Inc.; and NeuroSystec Corporation. The company was co-founded by Felix Theeuwes, James E. Brown, and Thomas A. Schreck in 1998. DURECT is headquartered in Cupertino, California.
GENAERA CORPORATION (GENR)
Genaera Corporation, a biopharmaceutical company, develops medicines primarily for antiangiogenesis and respiratory diseases from genomics and natural products. Its product candidates include EVIZON for the treatment of ophthalmic indications and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN, a mucoregulator to treat the overproduction of mucus and secretions involved in various forms of chronic respiratory disease. Genaera Corporation was incorporated in 1987 and is headquartered in Plymouth Meeting, Pennsylvania.
NASTECH PHARMACEUTICAL COMPANY INC (NSTK)
Nastech Pharmaceutical Company, Inc., a pharmaceutical company, engages in the development and commercialization of products based on proprietary molecular biology-based intranasal drug delivery technology for delivering both small and large molecule drugs. It develops a diverse product portfolio across various therapeutic areas, including products targeted for the treatment of obesity, sexual dysfunction, pain management, and osteoporosis. The company has collaboration agreements with Merck & Co., Inc. for the development of Peptide YY, an obesity product candidate, which is in Phase I clinical trial. In addition, it develops products for osteoporosis; and in collaboration with Par Pharmaceutical, Inc., it develops Parathyroid Hormone (PTH), which is in Phase I clinical trials and calcitonin-salmon intranasal spray. The company was founded in 1983 and is headquartered in Bothell, Washington.
EPIX PHARMACEUTICALS INC (EPIX)
EPIX Pharmaceuticals, Inc. engages in the discovery and development of pharmaceuticals for imaging. The company offers imaging agents, which enable physicians to use magnetic resonance imaging (MRI) to obtain detailed information about specific disease processes. Its pipeline of MRI imaging pharmaceuticals include Vasovist, which completed phase III clinical trial for the detection of vascular disease; and EP-2104R, an injectable MRI contrast agent to detect blood clots using MRI. EPIX Pharmaceuticals has strategic alliance and collaboration agreements with Schering AG, Tyco/Mallinckrodt, GE Medical Systems, Philips Medical Systems, and Siemens Medical Systems. The company was formed as Metasyn, Inc. in 1988 and changed its name to EPIX Medical, Inc. in 1996. Further, EPIX Medical changed its name to EPIX Pharmaceuticals, Inc. in 2004. EPIX Pharmaceuticals is based in Cambridge, Massachusetts.
POZEN, Inc., a pharmaceutical company, develops therapeutic advancements for diseases with unmet medical needs. It focuses primarily on developing products for the treatment of migraine, acute, and chronic pain, as well as other pain-related indications. The company's lead product candidate is Trexima, which is being developed in collaboration with GlaxoSmithKline for the treatment of acute migraine. Trexima is GlaxoSmithKline's proposed brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with RT Technology; and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID). The company is also developing product candidates that combine an acid inhibitor with an NSAID. POZEN has two product candidates in development that combine a proton pump inhibitor with an NSAID in a single tablet. They include PN 100, a combination of lansoprazole and naproxen; and PN 200, a combination of omeprazole and naproxen. These product candidates are intended to provide management of pain and inflammation associated with conditions, such as osteoarthritis, with fewer gastrointestinal complications compared to an NSAID taken alone. POZEN was founded in 1996 and is headquartered in Chapel Hill, North Carolina.
NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cancer drugs for therapeutic applications in the United States. The company's drugs portfolio are based on two proprietary technology platforms, the NeoLipid liposomal drug delivery system, and a tumor-targeting toxin platform. Its products primarily include IL13-PE38QQR, a Phase III clinical trial product, which would be used for the treatment of glioblastoma multiforme, brain cancer; LE-SN38, a Phase I clinical trial product, for the treatment of colorectal cancer and other solid tumors; LEP-ETU, a Phase I clinical trial product, for the treatment of breast cancer, lung cancer, ovarian cancer, and other solid tumors; and LErafAON, a Phase I trail product, to be used for treating cancer. NeoPharm also develops NeoPhectin and NeoPhectin-AT, which are gene transfection kits. The company has a license agreement with Nippon Kayaku Co., Ltd., for the development and commercialization of IL13-PE38QQR in Japan. The company was incorporated in 1990 under the name OncoMed, Inc. and changed its name to NeoPharm, Inc. in 1995. NeoPharm is headquartered in Lake Forest, Illinois.
VICAL INCORPORATED (VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. The company focuses on the development of biopharmaceutical product candidates based on its patented deoxyribonucleic acid (DNA) delivery technologies. It develops various DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer, and cardiovascular diseases. Vical primarily develops its cancer immunotherapeutics, Allovectin-7 and IL-2/Electroporation, as well as a plasmid DNA vaccine for cytomegalovirus. Allovectin-7, which completed its Phase II clinical trials, is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin, which together form a Class I Major Histocompatibility Complex antigen. Allovectin-7 is being developed as a treatment for metastatic melanoma, a form of skin cancer. IL-2/Electroporation program that is in Phase 1 clinical testing is a gene-based, electroporation enhanced delivery of interleukin-2, or IL-2, a potent immunotherapeutic agent, as a treatment for solid tumors, with an initial indication in metastatic melanoma. Vical also develops an anthrax vaccine, which is in Phase 1 clinical testing. The company was incorporated in 1987 and is based in San Diego, California.
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter & Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.
ORASURE TECHNOLOGIES INC (OSUR)
OraSure Technologies, Inc. engages in the development, manufacture, and marketing of oral specimen collection devices. Its products include Q.E.D. Saliva Alcohol Test and Intercept, a laboratory-based oral fluid drug test; OraSure HIV-1 oral fluid specimen device, a collection device that collects oral fluid to test for antibodies to the HIV-1 virus; OraQuick Rapid HIV-1 antibody test, a point-of-care test to aid in the diagnosis of infection to HIV-1 using a fingerstick and venipuncture whole blood specimen; Toxicology kits for use in testing blood, urine, hair, oral fluid, sweat, and other forensic samples. The company also offers enzyme immunoassay test kits and oral fluid collection devices, which are used to perform risk assessment testing of life insurance applicants and screen for drugs of abuse, nicotine use, and therapeutic drugs, to insurance laboratory clients; OraSure, a set of MICRO-PLATE products to the blood fractionation market for testing of plasma and related products; Cryosurgery for treating various superficial benign skin lesions, including warts, actinic keratoses, seborrheic keratoses, skin tags, age spots, condyloma acuminate, and molluscum; and Histofreezer portable cryosurgical system for cryosurgery. The company sells its products in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is headquartered in Bethlehem, Pennsylvania.
MARTEK BIOSCIENCES CORPORATION (MATK)
Martek Biosciences Corporation engages in the development, manufacture, and sale of products derived from microalgae and other microbes primarily in the United States. Its products include nutritional oils used in infant formula, nutritional supplements, and food fortification ingredients, and fluorescent markers for diagnostics and rapid miniaturized screening. The company's nutritional oils consist of fatty acid components, such as docosahexaenoic acid (DHA) and arachidonic acid (ARA). DHA and ARA help in developing the eyes and central nervous systems of newborns, and DHA helps in promoting adult mental and cardiovascular health. It develops fluorescent detection products from microalgae that connect fluorescent algal proteins to antibodies. These products and technologies enable researchers in drug discovery and diagnostics. Fluorescent detection products include Phycobiliproteins, which are classical direct fluorescent detection dyes and SensiLight dyes that are used to match the sensitivity of chemiluminescent methods. Martek Biosciences markets and sells its nutritional oils primarily to the infant formula and natural products industries. The company has a collaborative agreement with SemBioSys Genetics, Inc., a Canadian biotechnology company, to co-develop plant-based DHA products. Martek Biosciences was founded by Radmer in 1985. The company is based in Columbia, Maryland.
SIGA TECHNOLOGIES INC (SIGA)
SIGA Technologies, Inc. engages in the discovery, development, and commercialization of vaccines, antibiotics, and novel anti-infectives for the prevention and treatment of infectious diseases. It applies bacterial and viral genomics in the design and development of its products. The company offers products for use in defense against biological warfare agents, such as Smallpox and Arenaviruses. It has developed two methods in the development of vaccines, bacterial commensal vectors, which enables rapid production of live recombinant vaccines against biological agents; and surface protein expression system, used in the production of foreign proteins for use in subunit vaccine formulations. The company is also developing antibiotics to hit the bacterial adhesion organelles, as well as a technology for the mucosal delivery of its vaccines, which would allow the vaccines to activate the immune system at the mucus lined surfaces of the body, including the mouth, the nose, the lungs, and the gastrointestinal and urogenital tracts. The company's anti-infective product portfolio includes gram-positive antibiotic technology, gram-negative antibiotic technology, and broad-spectrum antibiotic technology targeted principally towards drug-resistant bacteria and hospital-acquired infections. SIGA Technologies has license agreements and collaborative research arrangements with Rockefeller University, Oregon State University, National Institutes of Health, Washington University, Regents of the University of California, and TransTech Pharma, Inc. The company was founded in 1995 and is headquartered in New York City.
THIRD WAVE TECHNOLOGIES INC (TWTI)
Third Wave Technologies, Inc. operates as a molecular diagnostics company in the United States. It engages in the development and marketing of molecular diagnostic solutions for various deoxyribonucleic acid and ribonucleic acid analysis applications, providing clinicians and researchers with molecular solutions. Its products include analyte specific reagents that allow laboratories to create assays to perform hepatitis C virus genotyping, to screen for cystic fibrosis and other inherited disorders, and to test for the Factor V Leiden, and a host of other mutations associated with predisposition to cardiovascular and other diseases. The company's products provide clinicians and researchers with solutions for diagnosis and treatment of disease. The company's molecular diagnostic products are used by clinical testing laboratories that perform prognostic, diagnostic, and monitoring testing. Third Wave Technologies was founded by Lance Fors in 1993. The company is headquartered in Madison, Wisconsin.
NOVEN PHARMACEUTICALS INC (NOVN)
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, and marketing of transdermal drug delivery technologies and prescription transdermal products. Its principal commercialized products include prescription transdermal drug delivery systems for use in menopausal hormone therapy. The company offers an estrogen patch for the treatment of menopausal symptoms marketed under the Vivelle name in the United States and Canada, and under Menorest name in Europe and certain other markets. Noven Pharmaceuticals also provides a second generation estrogen patch, the transdermal estrogen patch, under the Vivelle-Dot name in the United States and under Estradot name in various foreign countries. In addition, it developed a combination estrogen/progestin transdermal patch for the treatment of menopausal symptoms, which is marketed under the CombiPatch name in the United States and under the Estalis name in Europe and certain other markets. Noven sells its prescription patches approximately in 30 countries, including the United States, Canada, Japan, and Europe. It has collaboration with Novartis Pharma AG; Shire Pharmaceuticals Group plc; P&G Pharmaceuticals, Inc.; and Endo Pharmaceuticals, Inc. to develop a range of new patches. The company was incorporated in 1987 and is headquartered in Miami, Florida.
DISCOVERY LABORATORIES INC (DSCO)
Discovery Laboratories, Inc., a biopharmaceutical company, develops Surfactant Replacement Therapies for respiratory diseases. The company offers Surfaxin, a protein B-based agent, for the prevention of respiratory distress syndrome in premature infants. Discovery Laboratories provides Surfaxin, which is in Phase 2 clinical trials, for bronchopulmonary dysplasia in premature infants, neonatal respiratory disorders in premature infants, and prophylactic/early treatment of meconium aspiration syndrome in full-term infants. It also offers its products for the treatment of acute respiratory distress syndrome in adults in the intensive care unit, as well as a Phase 1b trial of its lung surfactant delivered as an inhaled aerosol for patients who suffer from asthma. In addition, the company evaluating the development of aerosolized formulations of its SRT to prevent or treat acute lung injury, COPD, rhinitis, sinusitis, sleep apnea, and otitis media. It has a strategic alliance with Quintiles Transnational Corp.; PharmaBio Development, Inc.; Chrysalis Technologies; and Laboratorios del Dr. Esteve S.A. The company is headquartered in Warrington, Pennsylvania.
THERAGENICS CORPORATION (TGX)
Theragenics Corporation provides brachytherapy and wound closure products. It operates through two segments, brachytherapy seed and CP Medical Wound Closure and Medical Products. The brachytherapy seed segment offers TheraSeed, a rice-sized palladium-103 device, used treat solid localized tumors, such as prostate cancer. This segment also manufactures and distributes I-Seed, an iodine-125 based medical device for the treatment of prostate cancer, as well as provides Intravascular Brachytherapy System that is designed to prevent restenosis or renarrowing of arteries. CP Medical Wound Closure and Medical Products segment manufactures and supplies sutures, cardiac pacing cables, brachytherapy needles/spacers/sleeves, and other related medical products for wound closure, cardiac pacing, and the general, dental, cosmetic and veterinary surgery markets. It distributes its products to physicians, hospitals, and other healthcare providers. Theragenics was incorporated in 1981 and is based in Buford, Georgia.
AMARIN CORPORATION PLC (AMRN)
Amarin Corporation plc, a neuroscience pharmaceutical company, engages in the development and commercialization of novel drugs for the treatment of neurological disorders affecting the central nervous system. The company's principal compound, Miraxion, is in phase III development for Huntington's disease. It also develops Miraxion for the treatment of other central nervous system disorders, including treatment unresponsive depression. The company, formerly known as Ethical Holdings plc, was incorporated in 1989 and is headquartered in London.
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. The company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma; and with MedImmune, Inc. to co-develop a therapeutic vaccine designed to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas. Cerus was incorporated in 1991 and is based in Concord, California.
BIOCRYST PHARMACEUTICALS INC (BCRX)
BioCryst Pharmaceuticals, Inc. engages in the design, optimization, and development of small-molecule drugs that treat cancer, cardiovascular, and autoimmune diseases, as well as viral infections. The company focuses on building potent, selective inhibitors of enzymes associated with targeted diseases. BioCryst Pharmaceuticals integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. Its lead product candidate, Fodosine, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is in a Phase IIa trial for patients with T-cell leukemia and in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma. The company's pipeline products include PNP Inhibitor (BCX-4208), Hepatitis C Polymerase Inhibitors, and Tissue Factor/Factor VIIa Inhibitors. PNP Inhibitor (BCX-4208), a phase I clinical trial product, is intended for the treatment of T-cell mediated autoimmune diseases, including psoriasis. Hepatitis C Polymerase Inhibitor, a product under lead optimization stage, is intended for the treatment of viral infections. Tissue Factor/Factor VIIa, a product under lead optimization stage, is intended for the treatment of acute coronary syndromes and complications associated with cardiovascular procedures. The company has strategic agreement with Sunol Molecular Corp. to conduct research and supply of protein targets for drug design for its cardiovascular program. BioCryst Pharmaceuticals was co-founded in 1986 by Charles E. Bugg, John A. Montgomery, and William M. Spencer, III. The company is headquartered in Birmingham, Alabama.
OXiGENE, Inc. engages in the research and development of products for the treatment of cancer and certain eye diseases. The company focuses on the development of products for application as direct cancer treatment agents, particularly vascular targeting agents (VTAs). It also investigates the use of certain products in the field of ophthalmology, in particular age-related macular degeneration and myopic macular degeneration. The company's technology, Combretastatin, is a family of proprietary small molecule anti-tumor VTAs. OXiGENE's CA4P compound targets the inner areas of the tumor. It is developing OXi4503 that targets blood vessels at the central core of the tumor, and appears to affect the vessels and tumor cells at the periphery. The CA4P is being tested in five human clinical trials in oncology, and one human clinical trial in ophthalmology. It is in Phase I/II combination clinical trial with Carboplatin and Paclitaxel in advanced ovarian cancer. In addition, a Phase II single agent trial in advanced and metastatic anaplastic thyroid carcinoma (ATC), and a Phase I/II combination trial in newly diagnosed ATC. OXiGENE is undertaking a Phase I/II combination trial with radiotherapy in head and neck, lung, and prostate cancers, as well as a Phase Ib combination trial with a monoclonal antibody in colorectal cancer. Its anti-tumor agent, OXi6197, reduces blood flow in newly formed tumor vasculature. The company is conducting Phase II single agent trial to treat a form of thyroid cancer, anaplastic thyroid carcinoma and a Phase II study for ATC to evaluate the mean survival time of patients. It is undertaking a Phase Ib study to evaluate the combination of CA4P with the radiolabeled anti-CEA monoclonal antibody A5B7. Additionally, the company has Phase I/II clinical trial for the nonlife threatening ocular disease, wet age-related macular degeneration. OXiGENE was incorporated in 1988 and is headquartered in Waltham, Massachusetts.
Axcan Pharma, Inc. engages in the research, development, marketing, and sale of pharmaceutical products for the treatment of gastrointestinal diseases and disorders. Its products include ULTRASE, PANZYTRAT, and VIOKASE for the treatment of gastrointestinal symptoms related to cystic fibrosis; URSO/URSO 250, URSO FORTE/URSO DS, and DELURSAN for the treatment of cholestatic liver diseases; SALOFALK and CANASA for the treatment of inflammatory bowel diseases; and CARAFATE/SULCRATE for the treatment of gastric duodenal ulcers. The company also develops various pharmaceutical projects, including ITAX for the treatment of functional dyspepsia. Axcan Pharma sells its products primarily to hospitals, wholesale drug companies, and distributors in North America and Europe. It has an exclusive license from Abbott Laboratories to develop, manufacture, and market Itopride in North America, the European Union, and Latin America. The company was founded in 1982 by Leon F. Gosselin. It was formerly known as 115391 Canada, Inc. and changed its name to Interfalk Canada, Inc. in 1983. Further, Interfalk Canada changed its name to Axcan Pharma, Inc. in 1994. Axcan Pharma is headquartered in Mont Saint-Hilaire, Canada.
PROGENICS PHARMACEUTICALS INC (PGNX)
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. It offers products for the areas of symptom management and supportive care, and the treatment of HIV infection and cancer. The company's methylnaltrexone is designed to reverse the side effects of opioid pain medications while maintaining pain relief and also for the management of post-operative bowel dysfunction caused by endogenous, or naturally occurring, opioids. The company is developing viral-entry inhibitors in the area of HIV infection, including PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5; PRO 542, a genetically engineered molecule designed to neutralize HIV by preventing it from attaching to the CD4 receptor on the surface of immune system cells; ProVax for the prevention of HIV infection or as a therapeutic treatment for HIV-positive individuals. The company, in collaboration with Cytogen Corporation, is developing immunotherapies for prostate cancer, including a human monoclonal antibody directed against prostate-specific membrane antigen, a protein found on the surface of prostate cancer cells. It is also developing vaccines designed to stimulate an immune response to PSMA. The company is also developing a cancer vaccine, GMK, which is in phase 3 clinical trials for the treatment of malignant melanoma. Progenics Pharmaceuticals has agreement with Wyeth Pharmaceuticals for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. The company was founded by Paul J. Maddon. Progenics Pharmaceuticals was incorporated in 1986 and is based in Tarrytown, New York.
HEMISPHERX BIOPHARMA INC (HEB)
Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development and manufacture of drugs for the treatment of viral and immune-based chronic disorders. Its products primarily include Ampligen and Alferon. Ampligen is a Phase III completed product for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), human immunodeficiency virus (HIV), and HIV/Hepatitis C co-infection. Alferon is an injectable formulation of natural alpha interferon for use in the treatment of genital warts. The company's Alferon is also in clinical development for the treatment of hepatitis C, multiple sclerosis, HIV, west Nile virus, and severe acute respiratory syndrome. In addition, the company's Alferon LDO is an experimental low-dose, oral liquid formulation of natural alpha interferon, which would be used for the treatment of viral diseases. Hemispherx Biopharma is headquartered in Philadelphia, Pennsylvania.
Pharmacyclics, Inc., a pharmaceutical company, develops products for the treatment of cancer, atherosclerosis, and other diseases. It offers Xcytrin, an anti-cancer agent designed to target cancer cells and, by disrupting cell metabolism, induce cell death through a cellular process, known as apoptosis. The company also develops Antrin angiophototherapy, which completed phase 1 clinical trails, for the treatment of atherosclerosis involving the coronary arteries of the heart. Pharmacyclics was co-founded by Richard A. Miller in 1991 and is headquartered in Sunnyvale, California.
TECHNE CORPORATION (TECH)
TECHNE Corporation, through its subsidiaries, engages in the development and manufacture of biotechnology products and hematology calibrators and controls. The company operates in two divisions, Biotechnology and Hematology. The Biotechnology division engages in the development and manufacture of cytokines and enzymes, antibodies, assay kits, clinical diagnostic kits, flow cytometry products, and intracellular cell signaling products. These products are sold to biomedical researchers and clinical research laboratories. The Hematology division develops and manufactures whole blood hematology controls and calibrators, linearity and reportable range controls, whole blood reticulocyte controls, whole blood flow cytometry controls, whole blood glucose/hemoglobin control, erythrocyte sedimentation rate control, and multipurpose platelet reference controls. These products are sold to hospitals and clinical laboratories to check the performance of hematology instruments. In addition, the company distributes biotechnology products in Europe. The company was founded in 1976 and is based in Minneapolis, Minnesota.
FORBES MEDI-TECH INC (FMTI)
Forbes Medi-Tech, Inc., a life sciences company, engages in the research, development, and commercialization of products for the prevention and treatment of cardiovascular disease. It develops cholesterol-lowering agents used both as pharmaceutical therapeutics and functional food ingredients. The company's lead drug candidate is FM-VP4, a cholesterol-lowering prescription pharmaceutical candidate, which completed a Phase II clinical trial in Europe. FM-VP4 is a cholesterol absorption inhibitor, a relatively new class of cholesterol-lowering pharmaceutical that would have therapeutic applications alone or in conjunction with other cholesterol-lowering therapies. The company also markets two nutraceutical products, Reducol and Phyto-S-Sterols. These products are plant sterol-based cholesterol-lowering food and dietary supplement ingredients derived from by-products of the forestry industry. Its drug development program includes FM-VA12, a single molecular entity that has been shown in animal studies to inhibit cholesterol absorption; and FM-VP24, an analogue, which early stage research shows inhibits cholesterol absorption while also exhibiting anti-inflammatory activity. Forbes has strategic partnership with Chusei (U.S.A.), Inc. The company was incorporated in 1985 as Amber Resources, Ltd. and changed its name to Forbes Medi-Tech, Inc. in 1992. Forbes is headquartered in Vancouver, Canada.
ALLIANCE IMAGING INC (AIQ)
Alliance Imaging, Inc. provides shared-service and fixed-site diagnostic imaging services to hospitals and other healthcare providers in the United States. It offers various services that include systems operation; equipment maintenance; and upgrading and management of day-to-day operations. The company also operates various free-standing imaging centers and fixed-site imaging centers primarily in partnerships with hospitals or health systems. In addition, Alliance Imaging provides ancillary services, including marketing support, education and training, and billing assistance. As of September 30, 2005, it had 497 diagnostic imaging systems comprising 350 magnetic resonance imaging systems and 58 positron emission tomography and positron emission tomography/computed tomography systems. The company serves various customers, including equipment manufacturers, community medical centers, university hospitals, community medical centers, clinics, and physical groups in 44 states. Alliance Imaging, Inc. was founded by Richard Zehner in 1983. The company is based in Anaheim, California.
ALBANY MOLECULAR RESEARCH INC (AMRI)
Albany Molecular Research, Inc. operates as a chemistry-based drug discovery and development company. It develops small molecule prescription drugs. Albany offers drug lead discovery, medicinal chemistry, chemical development, and analytical chemistry services. The company conducts research and development projects; and collaborates with various pharmaceutical, biotechnology, and genomics companies. It also provides discovery technologies, including isolation, purification, structure elucidation, and sample collection libraries from microbial and botanical sources, computational chemistry, virtual screening, microbiology, fermentation, asymmetric synthesis, and high throughput metabolic screening. The company offers its services to pharmaceutical companies, biotechnology companies, agricultural companies, fine chemical companies, and contract chemical manufacturers. Albany Molecular Research was founded in 1991 and is based in Albany, New York.
SCICLONE PHARMACEUTICALS INC (SCLN)
SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics to treat life-threatening diseases. Its products include ZADAXIN is in phase 3 hepatitis C virus clinical trials, as well as in other late-stage clinical trials for the treatment of hepatitis B virus and certain cancers. The company also develops SCV-07, which is in preclinical studies, for the treatment of viral and other infectious diseases. The company sells its products primarily in Asia, the Middle East, and Latin America. SciClone Pharmaceuticals was founded in 1989 and is headquartered in San Mateo, California.
CYTOGEN CORPORATION (CYTO)
Cytogen Corporation, an oncology-focused biopharmaceutical company, engages in licensing, developing, and commercializing therapeutic and molecular imaging/diagnostic products. The company markets QUADRAMET and PROSTASCINT products. QUADRAMET, a samarium Sm-153 lexidronam injection for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma, and other types of cancer. PROSTASCINT is a capromab pendetide kit for the preparation of Indium In-111 capromab pendetide, a monoclonal antibody-based agent targeting prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. It also engages in the development of therapeutics targeting PSMA, a protein expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. The company's product candidates and pipeline includes rs PSMA protein vaccine, an in vivo vaccine consisting of recombinant soluble PSMA combined with an immune stimulant to induce an immune response; PSMA viral vector vaccine, an in vivo vaccine that utilizes viral vectors designed to deliver the PSMA gene to immune system cells in order to generate potent and specific immune response; and PSMA monoclonal antibodies, a fully-human monoclonal antibodies that bind to the three-dimensional structure of PSMA as presented on cancer cells, including naked, toxin-linked, and radio-labeled approaches. Cytogen Corporation also has marketing rights to COMBIDEX, an investigational functional molecular imaging agent consisting of iron oxide nanoparticles, which is being developed for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from noncancerous lymph nodes. The company was founded in 1980. It was incorporated under the name Hybridex, Inc. in March 1980 and changed its name to Cytogen Corporation in April 1980. The company is headquartered in Princeton, New Jersey.
ImmunoGen, Inc. engages in the discovery and development of therapeutic monoclonal antibodies and treatments in the field of oncology in the United States and the United Kingdom. It develops novel, targeted therapeutics using its tumor-activated prodrug (TAP) technology, which uses monoclonal antibodies to deliver potent cell-killing agents. The company's two leading product candidates include huN901-DM1 and huC242-DM4, which are in clinical testing stage. Its huN901-DM1 product candidate consists of the huN901 antibody, which binds to the CD56 antigen, a cytotoxic agent. The company's second clinical TAP product candidate, huC242-DM4, consists of the humanized C242 monoclonal antibody with its cytotoxic agent attached and is in development for the treatment of colorectal, pancreatic, and other cancers. ImmunoGen also licenses its TAP technology to other biotechnology and pharmaceutical companies. ImmunoGen has collaborative partnerships with sanofi-aventis, Biogen Idec, Inc.; Boehringer Ingelheim International GmbH; Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Abgenix, Inc.; Genentech, Inc.; and GlaxoSmithKline plc. The company was organized in 1981 and is headquartered in Cambridge, Massachusetts.
KOSAN BIOSCIENCES INCORPORATED (KOSN)
Kosan Biosciences Incorporated, a biotechnology company, develops drug candidates from a class of natural product compounds known as polyketides. The company has collaboration agreements with Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche, Ltd. to co-develop and commercialize KOS-862 and KOS-1584 product candidates that are epothilones for the treatment of cancer. KOS-862 is in Phase II and Phase Ib clinical trials, and KOS-1584 is in a Phase I clinical trial. In addition, Kosan Biosciences develops 17-AAG and other analogs of geldanamycin; and KOS-1022, a water-soluble and orally-available analog of geldanamycin for the treatment of cancer. 17-AAG is in Phase II and Phase Ib combination clinical trials, as well as KOS-1022 is in Phase I clinical trials. The company was co-founded by Daniel V. Santi and Chaitan S. Khosla. Kosan Biosciences was founded in 1995 and is based in Hayward, California.
COLLAGENEX PHARMACEUTICALS INC (CGPI)
CollaGenex Pharmaceuticals, Inc. and its subsidiaries (CPI) operate as a specialty pharmaceutical company. It focuses on developing and marketing proprietary medical therapies to the dental and dermatology markets. The company's primary product, Periostat, is an orally administered, prescription dental pharmaceutical product to treat adult periodontitis. CollaGenex markets proprietary dental products of Atrix Laboratories, Inc. These products include Atridox, Atrisorb FreeFlow, and Atrisorb-D. Atridox is a locally-applied and antimicrobial therapy for the treatment of chronic adult periodontitis. Atrisorb FreeFlow is used in the surgical treatment of periodontal defects to help regenerate tissue. Atrisorb-D reduces the incidence of infections during guided tissue regeneration procedures. The company also markets Pandel, a prescription midpotency topical corticosteroid product licensed from Altana, Inc. In addition, it develops a pipeline of products, which are in clinical and preclinical development. These products are based on its proprietary platform technologies, IMPACs and Restoraderm. CPI distributes Periostat and Pandel through drug wholesalers in the United States. The company distributes the Atrix dental products through a specialty distributor who sells these products directly to dental practitioners in the United States and Puerto Rico. CollaGenex was founded in 1992 as CollaGenex, Inc. and changed its name to CollaGenex Pharmaceuticals, Inc. in 1996. The company is based in Newtown, Pennsylvania.
CryoLife, Inc. engages in the preservation and distribution of human tissues for cardiovascular, vascular, and orthopedic transplant applications. The company also engages in the development and commercialization of implantable medical devices, including its BioGlue Surgical Adhesive (BioGlue); the CryoLife-O'Brien aortic heart valve, a glutaraldehyde-fixed stentless porcine heart valve; and SynerGraft processed bovine vascular grafts for use as arteriovenous access devices. It distributes preserved human cardiovascular, vascular, and orthopedic tissue in the United States, Canada, and Europe. CryoLife distributes BioGlue in the United States and Europe for vascular applications, as well as for pulmonary indications, such as the repair of air leaks in lungs, and soft tissue repair procedures. The company markets the SynerGraft processed bovine vascular graft in Europe and the Middle East. It markets its CryoLife-O'Brien aortic heart valve in Europe and certain other territories outside the U.S. CryoLife was founded in 1984. The company is headquartered in Kennesaw, Georgia.
MERIDIAN BIOSCIENCE INC (VIVO)
Meridian Bioscience, Inc. operates as an integrated research, development, manufacturing, marketing, and sales organization in the field of life science. It develops, manufactures, and distributes diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases; and bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers, as well as provides contract manufacturing service of proteins and other biologicals for use by biopharmaceutical and biotechnology companies that are engaged in research for new drugs and vaccines. The company's product technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. It markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, and diagnostics manufacturers in approximately 60 countries worldwide, through direct sales force and independent distributors. The company was founded in 1976 and is based in Cincinnati, Ohio.
CEL-SCI CORPORATION (CVM)
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer and infectious diseases. The company owns a pre-clinical technology called ligand epitope antigen presentation system (L.E.A.P.S) that designs and synthesizes proprietary peptide immunogens. Its products include Multikine, an immunotherapeutic agent that is used for the treatment of cancer and CEL-1000 peptide, a product developed through its L.E.A.P.S, which provides protection in animals against malaria, herpes, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was formed in 1983 and is headquartered in Vienna, Virginia.
CORTEX PHARMACEUTICALS INC (COR)
Cortex Pharmaceuticals, Inc. engages in the discovery and development of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE drugs for the treatment of alzheimer's disease, mild cognitive impairment, schizophrenia, depression, narcolepsy, hyperactivity disorder, autism, fragile X, stroke, traumatic brain and spinal cord injury, parkinson's disease, and other neurological diseases. Its lead product includes AMPAKINE CX717, which has completed phase II clinical trial. The company has research collaboration agreements with N.V. Organon, which grants Organon rights to develop and commercialize the company's AMPAKINE technology for the treatment of schizophrenia and depression; and Les Laboratoires Servier that would allow Servier to develop and commercialize the company's AMPAKINE technology as a treatment for memory impairment associated with aging and neurodegenerative diseases. Cortex Pharmaceuticals was founded in 1987 and is based in Irvine, California.
AVANT IMMUNOTHERAPEUTICS INC (AVAN)
AVANT Immunotherapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization vaccines and therapeutics that address various applications, including cardiovascular, viral, and bacterial diseases. The company markets Rotarix for rotavirus infection, and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. Its immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines, including CholeraGarde for cholera, Ty800 for typhoid fever, and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages, which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines, and other food safety and animal health vaccines. The company has product development and licensing agreements with GlaxoSmithKline plc; Pfizer, Inc; DynPort Vaccine Company LLC; and Lohmann Animal Health International. AVANT Immunotherapeutics was organized in 1983 and is based in Needham, Massachusetts.
ArQule, Inc., a biotechnology company, engages in the research and development of small-molecule cancer therapeutics based on its Activated Checkpoint Therapy (ACT) platform. The ACT platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. Its primary product consists of ARQ 501, a Phase I oncology product for cancer patients with solid tumors. The company also has products in preclinical and research stages. ArQule was founded in 1993 and is headquartered in Woburn, Massachusetts.
TRINITY BIOTECH PLC (TRIB)
Trinity Biotech Plc engages in the development, manufacture, and marketing of diagnostic test kits used for the clinical laboratory and point-of-care segments of the diagnostic market. Its test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune disorders. The company also provides raw materials to the life sciences industry. Trinity Biotech sells its products through its sales force and a network of distributors and strategic partners in the United States and internationally. The company was co-founded by Ronan O'Caoimh and Denis R. Burger in 1992. Trinity Biotech is headquartered in Bray, Ireland.
Crucell N.V. engages in the discovery, development, and production of various biopharmaceutical products for the prevention and treatment of infectious diseases using its proprietary technologies. It develops vaccines and antibodies against influenza, West Nile virus, Ebola, malaria, tuberculosis, and rabies using PER.C6, AdVac, and MAbstract technologies. The company's PER.C6 technology encompasses a human cell line production system to develop biopharmaceutical products. Its AdVac technology is a recombinant vector technology that develops novel adenoviral-based products. Crucell's MAbstract phage antibody display technology is used to discover disease associated molecules and develop human antibodies. The company licenses its technologies to pharmaceutical and biotechnology companies. Crucell has a research and licensing agreement with ACE BioSciences A/S to discover antibody therapies to combat serious iatrogenic infections, including those caused by antibiotic-resistant bacteria; and a research and development agreement with the Walter Reed Army Institute of Research to evaluate Crucell's PER.C6 technology for the development of vaccines against the flaviviruses dengue fever and Japanese encephalitis. The company is headquartered in Leiden, the Netherlands.
TITAN PHARMACEUTICALS INC (TTP)
Titan Pharmaceuticals, Inc., a biopharmaceutical company, develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone diseases, and other disorders. It offers Probuphine, Iloperidone, Spheramine, DITPA, and Gallium maltolate. Probuphine is phase III clinical study for the treatment of opiate addiction and chronic pain. Iloperidone is in phase III for the treatment of schizophrenia and related psychotic disorders. Spheramine is in phase IIb for the treatment of advanced Parkinson's disease. DITPA is in phase II for the treatment of congestive heart failure and hyperlipidemia. Gallium maltolate is in phase I for the treatment of bone related diseases and other disorders. Titan Pharmaceuticals was incorporated in 1992 and is based in South San Francisco, California.
ELITE PHARMACEUTICALS INC (ELI)
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled release products. The company markets Lodrane 24 through ECR Pharmaceuticals and has six drug products under development in the therapeutic areas that cover therapeutic areas for pain, angina, hypertension, cardiovascular, allergy, and infection. Elite Pharmaceuticals has an agreement with Orit Laboratories, LLC to co-develop and commercialize an extended release drug product for treatment of anxiety. The company was formed in 1984 and is based in Northvale, New Jersey.
REPLIGEN CORPORATION (RGEN)
Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION (IART)
Integra LifeSciences Holdings Corporation engages in the development, manufacture, and marketing of medical devices for use in neuro-trauma, neurosurgery, reconstructive surgery, and general surgery. Its product groups include monitoring products, implants, instruments, and private label products. The company's monitoring products include intracranial pressure (ICP) monitoring systems, cerebral blood flow and ICP systems, oxygen monitoring systems, cranial access and cerebrospinal fluid drainage systems, epilepsy monitoring electrodes, and electroencephalogram, evoked potential, and electromyography electrodes, as well as disposables and other supplies. Its implants include absorbable collagen products, skin replacement and engineered wound dressings, hydrocephalus management products, peripheral nerves repair and protection products, hydrocephalus management, small bone and joint fixation devices and instruments, and hemodynamic shunts. The company's instruments include ultrasonic aspirator, cranial stabilization and positioning systems, halo retractor system, electro-surgery generators, neurosurgical and spinal instruments, reconstructive and plastic surgery instruments, harvesting and conditioning skin grafts devices, and spinal specialties. Integra LifeSciences sells its products primarily through catalogs and telemarketing to neurologists, hospitals, sleep clinics, and other physicians. The company also distributes various disposables and supplies, including surface electrodes, needle electrodes, recording transducers and stimulators, and respiratory sensors. Integra LifeSciences Holdings was founded in 1989 and is based in Plainsboro, New Jersey.
SEQUENOM, Inc., a genetics company, provides genetic analysis products that translate genomic science into superior solutions for biomedical research and molecular medicine. It primarily offers MassARRAY system that includes hardware, software, and consumable products. The MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. The system delivers data from biological samples and genetic target material that is available in trace amounts. The company offers its products primarily to pharmaceutical and biotechnology companies, laboratories, and governmental and other research institutions in North America, Europe, and Asia. It has strategic collaboration agreements with Bioscientia, Siemens Medical Solutions, and Procter & Gamble Pharmaceuticals. SEQUENOM was established in 1994 and is headquartered in San Diego, California.
Avigen, Inc., a development stage company, focuses on the acquisition, development, and commercialization of therapeutics to treat serious disorders, primarily for neurological conditions. It acquires or in-license later stage drug development candidates. Avigen was established in 1992 and is headquartered in Alameda, California.
AMDL, Inc., a theranostics company, engages in both the detection and treatment of cancer. It develops, manufactures, markets and sells various immunodiagnostic kits. Its products include DR-70, a test kit that is used in the detection of approximately 13 different types of cancer, including lung, stomach, breast, rectal, colon, and liver; and Pylori-Probe, which is cleared for sale in the United States. The company also offers private label test kits to underserved international markets through distributor relationships and to domestic markets through strategic partnerships and relationships with diagnostic companies. AMDL was incorporated in 1988 and is based in Tustin, California.
NEUROBIOLOGICAL TECHNOLOGIES INC (NTII)
Neurobiological Technologies, Inc., a biotechnology company, engages in the acquisition and development of central nervous system related drug candidates. It focuses on therapies for neurological conditions that occur in connection with dementia, alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer. Neurobiological Technologies offers Memantine an orally dosed compound used for the treatment of alzheimer's disease and neuropathic pain in the United States and Europe. The company also develops Viprinex, which is a late-stage reperfusion therapy for use in the treatment of acute ischemic stroke. Neurobiological Technologies has a strategic research and marketing cooperation agreement with Merz Pharmaceuticals GmbH and Children's Medical Center Corporation to further the clinical development and commercialization of Memantine. The company was founded by Enoch Callaway and John B. Stuppin in 1987. Neurobiological Technologies is based in Emeryville, California.
CARRINGTON LABORATORIES INC (CARN)
Carrington Laboratories, Inc. operates as a research-based biopharmaceutical and consumer products company in the United States and internationally. The company manufactures and markets products for mucositis, radiation dermatitis, and wound and oral care utilizing the naturally-occurring polymeric carbohydrates. It operates in three divisions: Medical Services Division, Consumer Services Division, and DelSite Biotechnologies, Inc. The Medical Services Division sells medical products and provides manufacturing services to customers in medical markets. It offers various products comprising hydrogels, wound cleansers, hydrocolloids, advanced wound covering products, and incontinence-care products, which contain its proprietary medical-grade raw material Acemannan Hydrogel. The Consumer Services Division offers a nutraceutical raw material Manapol and other proprietary and nonproprietary raw materials to the nutraceutical and cosmetic customers; nutritional products under the AloeCeuticals brand; and skin care products under the Snow or Sun brand. This division also markets the bulk raw material Hydrapol powder to manufacturers of bath, beauty, and skin care products, as well as manufactures private-labeled products consisting of powders, creams, liquids, gels, drinks, tablets, and capsules to customer specifications. The company, through its subsidiary, DelSite Biotechnologies, Inc., engages in the research, development, and marketing of its proprietary GelSite technology for controlled release and delivery of bioactive pharmaceutical ingredients. Carrington Laboratories was founded in 1973 under the name Ava Cosmetics, Inc. and changed its name to Carrington Laboratories, Inc. in 1986. The company is headquartered in Irving, Texas.
SONUS PHARMACEUTICALS INC (SNUS)
Sonus Pharmaceuticals, Inc. engages in the development of drugs for the treatment of cancer and related therapies by utilizing its TOCOSOL technology platform. TOCOSOL technology platform uses vitamin E oil and tocopherol derivatives to solubilize and stabilize drugs for formulation of therapeutic drugs for cancer. The company's primary product TOCOSOL Paclitaxel is an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer, and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and is headquartered in Bothell, Washington.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products and services. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment comprises insulin franchise, including insulin analogues, human insulin and insulin-related sales, and oral antidiabetic drugs. The Biopharmaceutical segment includes therapy areas, such as hemostasis management, growth hormone therapy and hormone replacement therapy, and other products. Novo Nordisk distributes its products primarily through distributors and independent agents. The company markets its products primarily in North America, Japan, and Europe. Novo Nordisk has a collaboration agreement with Aurigene Discoveries Technologies, which encompasses a joint discovery effort by both the companies on a target covering the discovery and preclinical development of lead series at Aurigene. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
BENTLEY PHARMACEUTICALS INC (BNT)
Bentley Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. It focuses on developing, licensing, and sale of generic and branded pharmaceutical products and active pharmaceutical ingredients, and the manufacturing of pharmaceuticals for others; and research, development, and licensing/commercialization of advanced drug delivery technologies and pharmaceutical products. Bentley pharmaceuticals manufactures and markets approximately 120 pharmaceutical products for various dosage strengths and product formulations of approximately 30 chemical entities in four primary therapeutic areas: cardiovascular, gastrointestinal, neurological, and infectious diseases; as well as markets over-the-counter products. Its proprietary CPE-215 permeation technology enables the absorption of drugs across membranes of the skin, mouth, nose, vagina, and eye. This technology can be incorporated into various pharmaceutical formats and products, including those formulated as creams, ointments, gels, solutions, lotions, sprays, and patches. Bentley Pharmaceuticals sells its generic and branded products to physicians, pharmacists, and hospitals in Europe. In addition, the company offers biodegradable Nanocaplet technology for the delivery of macromolecule therapeutics. It has a strategic alliance with Teva Pharmaceutical Industries, Ltd. granting Bentley the right to register and market certain of Teva's pharmaceutical products in Spain; and with Perrigo Company to codevelop and market generic pharmaceutical products; as well as an agreement with Dong Sung Pharm. Co., Ltd. for the development of an intranasal spray formulation of insulin for the South Korean market. Bentley Pharmaceuticals is headquartered in Exeter, New Hampshire.
PHARMOS CORPORATION (PARS)
Pharmos Corporation, a bio-pharmaceutical company, engages in the discovery and development of drugs to treat neurological and inflammatory disorders. Its proprietary technology platform focuses on the discovery and development of synthetic cannabinoid compounds. The company's lead product candidate, Cannabinor, is a CB2-selective class compound in late-stage preclinical development, which would be used as an analgesic to treat moderate to severe pain of various etiologies. Its neuroprotective drug candidate, dexanabinol, a Phase IIa trial completed product, would be used as a preventive agent against post-surgical cognitive impairment. Pharmos's NanoEmulsion drug delivery system is in clinical-stage development for topical application of analgesic and anti-inflammatory agents. The company also has various other compounds in preclinical studies focusing on pain, multiple sclerosis, rheumatoid arthritis, and other disorders. Pharmos operates in the United States and Israel. The company, formerly known as Pharmatec, Inc., was incorporated in 1982. Pharmos is headquartered in Iselin, New Jersey.
HEALTHCARE TECHNOLOGIES LTD (HCTL)
Healthcare Technologies, Ltd. engages in the development, manufacture, and marketing of medical diagnostic kits; and provision of service tools and materials to diagnostic and biotech research professionals in laboratory and point of care sites. The company's principal products include immunoassays, such as SeroCT, SeroCP, and SeroCP Quant, that are used for the detection of antibodies specific to chlamydia; SeroFIA Chlamydia IgG, IgA, and IgM diagnostic kits based on the microimmunofluorescence techniques assay methodology; SeroMP IgG, IgM, and IgA diagnostic kits for the serological diagnosis of mycoplasma pneumoniae infections; SeroPertussis product line; and Uriscreen, a test kit for the screening of urinary tract infections. It also markets QuickStripe tests, which consist of a compact cassette-like plastic card that includes the components required to run the test. Healthcare Technologies also engages in the production and marketing of molecular biology-based gene-screening tools for the detection of certain gene-associated disorders in humans, including prenatal testing for diseases, such as cystic fibrosis, gaucher, and other diseases, and testing for predisposition to diseases, such as breast, ovarian and colon cancer, thrombosis, and certain cardiovascular diseases. Its offers its products and services to clinical laboratories, quality control departments of industrial firms, the ministry of health and defense, administrators in sick funds, and private health care institutions in Israel and internationally. The company was established in 1988. It was formerly known as Istec Healthcare Technologies, Ltd. and changed its name to Healthcare Technologies, Ltd. in December 1988. Healthcare Technologies is based in Petach Tikva, Israel.
Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel.
NEOSE TECHNOLOGIES INC (NTEC)
Neose Technologies, Inc., a biopharmaceutical company, engages in the research and development of proprietary drugs primarily therapeutic proteins. The company's products include GlycoPEG-EPO, which stimulates the production of red blood cells for the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure; and GlycoPEG-GCSF that stimulates the production of neutrophils for the treatment of neutropenia associated with myelosuppressive chemotherapy. Neose Technologies has collaborations with BioGeneriX, Novo Nordisk A/S, and MacroGenics, Inc. for the research and development of its GlycoAdvance and GlycoPEGylation technologies. Neose Technologies was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
LIFECORE BIOMEDICAL INC (LCBM)
Lifecore Biomedical, Inc. engages in the development, manufacture, and marketing of biomaterials and medical devices for use in various surgical markets. It operates in two segments, Hyaluronan and Oral Restorative. The Hyaluronan segment develops and manufactures products utilizing hyaluronan, a naturally occurring polysaccharide that is distributed in the extracellar matrix of connective tissues in both animals and humans. Hyaluronan is also used as a component in ophthalmic, orthopedic, and veterinary medical devices. It also offers FeHA Adhesion Prevention Solution that reduces the incidence of tissue adhesions following surgical trauma, as well as hyaluronan to other medical applications, such as wound care, aesthetic surgery, medical device coatings, tissue engineering, drug delivery, and pharmaceuticals. This segment markets its products through original equipment manufacturers and contract manufacturing alliances in ophthalmologic and orthopedic surgery and veterinary medicine. The Oral Restorative segment develops and markets precision surgical and prosthetic devices for the restoration of damaged or deteriorating dentition and associated support tissues. Its dental implants are permanently implanted in the jaw for tooth replacement therapy as long-term support for crowns, bridges, and dentures. This segment also offers bone regenerative products for the repair of bone defects resulting from periodontal disease and tooth loss; and professional support services to its dental surgery clients through education curricula. It markets its products directly to clinicians and dental laboratories in the United States, Germany, Italy, Sweden, and France; and through distributorship arrangements in other foreign locations. The company was incorporated as American Medical Research, Inc. in 1965 and changed its name to DIAGNOSTIC, INC. in 1968. Further, it changed its name to Lifecore Biomedical, Inc. in 1987. Lifecore Biomedical is headquartered in Chaska, Minnesota.
ORCHID CELLMARK INC (ORCH)
Orchid Cellmark, Inc. provides deoxyribonucleic acid (DNA) testing services that generate genetic profile information by analyzing an organism's unique genetic identity. The company focuses on DNA testing for human identity, as well as for animal and agricultural applications. In the human identity area, it provides DNA testing services for forensic, family relationship, and security applications. In the animal and agriculture field, the company provides DNA testing services for food safety and selective trait breeding. Orchid Cellmark conducts forensic DNA testing primarily for government agencies; family relationship testing services to both government agencies and private individuals; security DNA testing services to government agencies, commercial companies, and private individuals; and animal and agriculture DNA testing services for government agencies and commercial companies. It markets its services to customers based in North America and Europe. The company was organized in 1995 and was formerly known as Orchid Biocomputer, Inc. and changed its name to Orchid Biosciences, Inc. Subsequently, it changed it name to Orchid Cellmark, Inc. in June 2005. Orchid Cellmark is headquartered in Princeton, New Jersey.
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
ANIKA THERAPEUTICS INC (ANIK)
Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts.
QUESTCOR PHARMACEUTICALS INC (QSC)
Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of novel therapeutics for the treatment of neurological disorders with a focus on central nerves system. The company's primary product is H.P. Acthar Gel, a natural source of adrenocorticotropic hormone (ACTH), which provides prolonged release after intramuscular or subcutaneous injection. H.P. Acthar Gel is indicated for the treatment of acute exacerbations of multiple sclerosis, as well as for various other conditions. The company is in the process of building a development pipeline of additional prescription-only therapeutics, with primary focus on the field of neurology. Questcor is headquartered in Union City, California.
DUSA PHARMACEUTICALS INC (DUSA)
DUSA Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and marketing of a drug named 5-aminolevulinic acid (ALA). ALA is used in combination with appropriate light devices in order to detect or treat a variety of medical conditions, such as photodynamic therapy or photodetection. Its products include Levulan 20% topical solution using its Kerastick brand applicator, and BLU-U brand light unit for the treatment of actinic keratoses (AKs). AKs are precancerous skin lesions caused by chronic sun exposure that can develop over time into a form of skin cancer called squamous cell carcinoma. The company's products are used together to provide photodynamic therapy for the treatment of nonhyperkeratotic actinic keratoses of the face or scalp. Kerastick is a single-use, disposable applicator, which allows for the rapid preparation and uniform application of Levulan topical solution in standardized doses. In addition, the BLU-U is used without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. The company offers its products through direct and third party distributors in the United States. DUSA Pharmaceuticals was incorporated in 1991 and is headquartered in Wilmington, Massachusetts.
TARGETED GENETICS CORPORATION (TGEN)
Targeted Genetics Corporation engages in the research and development of gene therapy products and technologies for treating both acquired and inherited diseases. Its product candidates include tgAAVCF, a phase II clinical trial product, for treating cystic fibrosis; tgAAC94, a Phase I clinical trial AAV-based product, for the treatment of rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis; and tgAAC09, a phase I clinical trial AAV-based prophylactic vaccine candidate, for high risk populations in developing nations to protect against the progression of Human Immunodeficiency Virus (HIV) and infection to Acquired Immune Deficiency Syndrome (AIDS). The company also engages in exploring gene therapies for cardiovascular disease by applying its AAV vector technology to treating hyperlipidemia, the elevation of lipids, or fats, such as cholesterol in the bloodstream. Targeted Genetics was incorporated in 1989 and is based in Seattle, Washington.
GENELABS TECHNOLOGIES INC (GNLB)
Genelabs Technologies, Inc. engages in the discovery and development of pharmaceutical products to improve human health. It is developing Prestara (prasterone), an investigational drug for women with systemic lupus erythematosus. The company also pursues drug discovery of novel antiviral compounds for treatment of hepatitis C virus infections and advances preclinical development of compounds in this program. Genelabs Technologies has strategic collaborations with Watson Pharmaceuticals, Inc. and Tanabe Seiyaku Co., Ltd. for the development and commercialization of its investigational new drug. The company was founded in 1983 and is headquartered in Redwood City, California.
EXACT SCIENCES CORPORATION (EXAS)
EXACT Sciences Corporation utilizes applied genomics to develop screening technologies for use in the detection of cancer. Certain of its technologies are offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corporation of America Holdings. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. EXACT Sciences was founded in 1995 and is headquartered in Marlborough, Massachusetts.
NORTH AMERICAN SCIENTIFIC INC (NASI)
North American Scientific, Inc. engages in the manufacture, marketing, and sale of products for the radiation oncology community. It offers intensity modulated and image guided radiation therapy products and services, as well as brachytherapy seeds used in the treatment of prostate cancer. The company offers iodine-based and palladium-based implantable brachytherapy seeds for the treatment of prostate cancer. It also provides a line of brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. In addition, the company offers radiation sources and standards, which are used in various areas for calibration, measurement, analysis, and control; nuclear medicine; and catalog and customized products for commercial laboratories serving the environmental sector. Further, it manufactures other radioisotopic products used in various medical, environmental, research, and industrial applications. The company's customers include federal and state governmental agencies, medical equipment manufacturers, nuclear utilities, and private organizations. North American Scientific was incorporated in 1987 and is headquartered in Los Angeles, California.
Novogen Limited, a pharmaceutical company, engages in the discovery, development, manufacture, and marketing of products based on the isoflavoniod technology. Its product development program comprises a novel range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones. The company's products include Promensil, which provides natural relief from the symptoms of menopause, such as hot flushes and night sweats; Trinovin, which maintains normal prostate and urinary function, health and quality of life in men; and Rimostil that maintains bone and cholesterol health, and also to promote health and well-being in women after menopause. In addition, Novogen develops phenoxodiol, which is in phase II clinical trials for the treatment of prostate cancer, ovarian cancer, renal cancer, and squamous cell carcinomas of the cervix, vagina, and vulva. It is also developing NV-04, a cardiovascular drug candidate; and NV-07, an anti-inflammatory drug candidate. The company sells its products through its distributors and other third parties in Australia, New Zealand, the United States, Canada, and certain European countries. Novogen was founded by Graham E. Kelly in 1994. It was formerly known as Norvet Limited. The company is headquartered in North Ryde, Australia.
ISTA PHARMACEUTICALS INC (ISTA)
ISTA Pharmaceuticals, Inc. engages in the development and commercialization of products for serious diseases and conditions of the eye. Its product pipeline includes Vitrase, a proprietary formulation of ovine hyaluronidase for the treatment of vitreous hemorrhage, for use as a spreading agent to facilitate the absorption and dispersion of other injected drugs, as well as for the treatment of diabetic retinopathy; Istalol, a topical solution of timolol, for the treatment of glaucoma, a chronic disease that gradually reduces eyesight; Xibrom, a topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation; Ecabit sodium for dry eye syndrome;and Caprogel, a topical gel formulation of aminocaproic acid, for the treatment of hyphema. ISTA Pharmaceuticals has collaborations with Allergan, Inc.; Otsuka Pharmaceutical Co., Ltd.; Senju Pharmaceuticals Co., Ltd.; and Eastern Virginia Medical School. The company was founded in 1992 as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in 2000. ISTA Pharmaceuticals is headquartered in Irvine, California.
NEOGEN CORPORATION (NEOG)
Neogen Corporation engages in the development, manufacture, and sale of various products for food safety testing and animal health applications. The company operates in two segments, Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect dangerous and unintended substances in food and animal feed, such as foodborne pathogens, food allergens, natural toxins, genetic modifications, ruminant by-products, drug residue, pesticide residue, disease infections, and general sanitation concerns. The Animal Safety segment produces and markets pharmaceuticals, vaccines, veterinary instruments, topicals, and diagnostic products for the detection of abused and therapeutic drugs in animals and animal products. It also produces and markets rodenticides for the control of rats and mice in and around agricultural, food production, and other facilities. The company, through its direct sales staff and distributors, sells its products primarily in the United States, South and Central America, Canada, Asia, and Europe. Neogen was formed in 1981 and is headquartered in Lansing, Michigan.
CARDIOTECH INTERNATIONAL INC (CTE)
CardioTech International, Inc. engages in the development and manufacture of small bore vascular grafts or synthetic blood vessels for the treatment of cardiovascular disease. It offers oxygenators, cardiovascular tubing systems, arterial filters, cardiotomy reservoirs, venous reservoirs, oxygen saturation monitors, orthofuser, cardioplegia units, and critical care central venous access catheters and ports that are used during open heart surgery, as well as develops CardioPass synthetic coronary artery bypass graft to treat coronary artery disease. The company also manufactures medical disposables on an original equipment manufacturing basis for the cardiology, interventional radiology, and critical care markets; supplies specialized disposable medical devices to medical device companies; and provides contract services. In addition, CardioTech International develops, manufactures, and markets polyurethane-based biomaterials for use in acute and chronically implanted devices, such as stents, artificial hearts, and vascular ports. It distributes products primarily through medical distributors in the United States and internationally. The company was founded in 1993 and is headquartered in Wilmington, Massachusetts.
LA JOLLA PHARMACEUTICAL COMPANY (LJPC)
La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the research and development of pharmaceutical products in the United States. Its principal product in development is Riquent, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. Riquent is in Phase III clinical trial. The company also develops small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. La Jolla Pharmaceutical Company was founded in 1989 and is based in San Diego, California.
NEUROGEN CORPORATION (NRGN)
Neurogen Corporation engages in the discovery and development of small molecule drugs for neurological diseases, pain, inflammation, and metabolic diseases. The company, through its Accelerated Intelligent Drug Discovery platform, focuses on the development of drugs primarily relating to insomnia, pain, depression/anxiety, and obesity/diabetics. It lead proprietary drug candidate for insomnia includes NG2-73, a Phase I human testing product. The company has collaboration and license agreement with Merck Sharp & Dohme Limited for research, development, and commercialization of small molecule medicines, which work by targeting the vanilloid receptor, a key integrator of pain signals in the nervous system. The company also has collaborative research agreement with Pfizer, Inc. for the development of gamma-aminobutyric acid -based drugs for the treatment of sleep disorders. Neurogen was incorporated in 1987 and is based in Branford, Connecticut.
IOMED, Inc. engages in the development, manufacture, and marketing of drug delivery systems used primarily to treat acute local inflammation in the physical and occupational therapy, and sports medicine markets. It offers iontophoresis technology primarily for transdermal drug delivery and for the treatment of ophthalmic disease. The company's proprietary iontophoresis system comprises a reusable dose controller and single use, disposable active transdermal patch kits. It also markets a self-contained iontophoresis system, the Companion 80 that provides a Mobile Solution allowing the patient to resume daily activity and the clinician to optimize the use of patient time in the clinic. The company also offers Numby Stuff, for the delivery of Iontocaine with the phoresor system. Numby Stuff provides noninvasive, local dermal anesthesia with rapid onset, and can be used prior to needle sticks, IV starts, lumbar punctures, PICC insertions, fine needle and skin biopsies, and other minor dermatological surgeries. In addition, the company develops the OcuPhor system to deliver drug compounds noninvasively and site-specifically to posterior segments of the eye; and IontoDex, an active drug transport system designed for patient in-home use to treat acute local inflammation. IOMED distributes its products through a network of medical supply dealers, independent sales representatives, and national distribution partners to the physical and occupational therapy, sports medicine, and other healthcare markets. The company was incorporated in 1974 as Motion Control, Inc. and changed its name to IOMED, Inc. in 1987. IOMED is based in Salt Lake City, Utah.
QUIGLEY CORPORATION (QGLY)
The Quigley Corporation engages in the development, manufacture, and distribution of homeopathic and health products. It operates in four segments: Cold Remedy, Health and Wellness, Contract Manufacturing, and Ethical Pharmaceutical. The Cold Remedy segment offers Cold-Eeze, a zinc gluconate glycine formulation. Cold-Eeze is an over-the-counter consumer product used to reduce the duration and severity of the common cold; and is sold in lozenge, sugar-free tablet, and gum forms. The Health and Wellness segment specializes in the development and distribution of proprietary health and wellness products, including herbal vitamins and dietary supplements for the human condition, primarily within the United States. The Contract Manufacturing segment produces lozenge product. It warehouses and ships the company's Cold-Eeze products. This segment also produces a variety of hard and organic candy for sale to third party customers, as well as engages in contract manufacturing activities for nonrelated entities. The Ethical Pharmaceutical segment involves in the research and development of naturally derived prescription drugs, cosmeceuticals, and dietary supplements. The Quigley was organized in 1989 by Guy J. Quigley and Charles A. Phillips. The company is headquartered in Doylestown, Pennsylvania.
No description available.
Heska Corporation engages in the discovery, development, manufacture, marketing, sale, and distribution of veterinary products. The company operates in two segments, Core Companion Animal Health (CCA); and Other Vaccines, Pharmaceuticals, and Products (OVP). The CCA segment offers diagnostic and monitoring instruments and supplies; single use diagnostic and other tests; vaccines; and pharmaceuticals, primarily for canine and feline use. This segment primarily provides various products, including handheld electrolyte instrument, chemistry instrument, and hematology instrument and their consumables. The OVP segment offers private label vaccine and pharmaceuticals, primarily for cattle, as well as for other animals, including small mammals, horses, and fish. The company sells its products directly, as well as through independent third party distributors and other distribution relationships. The company was incorporated as Paravax, Inc. in 1988 and changed its name to Heska Corporation in 1995. Heska is headquartered in Loveland, Colorado.
PRAECIS PHARMACEUTICALS INCORPORATED (PRCS)
PRAECIS PHARMACEUTICALS INCORPORATED, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human diseases. It provides Plenaxis, a gonadotropin releasing hormone antagonist approved for use in prostate cancer patients as a depot formulation in the United States, as well as Apan for the treatment of Alzheimer's disease. The company also offers a MetAP-2 inhibitor, PPI-2458, which is in clinical development for nonHodgkin's lymphoma and solid tumors; and a drug discovery technology, Direct Select that enables the generation and use of ultra-large libraries for the discovery of orally active compounds for drug development. PRAECIS PHARMACEUTICALS' research and development pipeline includes clinical programs in Alzheimer's disease, nonHodgkin's lymphoma, and androgen-independent prostate cancer, as well as certain early stage discovery projects. It sells its products directly to pharmaceutical distributors and pharmacies. The company was founded in 1993 by Malcolm L. Gefter. It was formerly known as Pharmaceutical Peptides, Inc. and changed its name to PRAECIS PHARMACEUTICALS INCORPORATED in 1997. PRAECIS PHARMACEUTICALS is headquartered in Waltham, Massachusetts.
United-Guardian, Inc. engages in the research, product development, manufacture, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. The company operates through two divisions, Guardian Laboratories and the Eastern Chemical Corporation. The Guardian Laboratories division provides LUBRAJEL, which is a line of nondrying water-based moisturizing and lubricating gels; RENACIDIN, a urological prescription drug; CLORPACTIN, a microbicidal product. The company also offers KLENSOFT, a surface active agent, is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; Confetti Dermal Delivery Flakes that incorporates various functional oil-soluble ingredients into colorful flakes that can be added to, and suspended in, various water-based products; RAZORIDE, which is a hypo-allergenic, nonfoaming, and water-based shaving product with lubricity and moisturizing properties; UNITWIX is a cosmetic additive used as a thickener for oils and oil-based liquids; DESELEX is a replacement for phosphates in detergents; LUBRASLIDE and a related product, B-122(TM), powdered lubricants used in the manufacture of cosmetics, such as pressed powders, eye liners, and rouges; HYDRAJEL PL and HYDRAJEL VM are personal lubricants and moisturizers developed for the feminine personal care market; and ORCHID COMPLEX for skin creams, lotions, cleansers, and other cosmetics. The Eastern Chemical Corporation division distributes a line of organic chemicals, research chemicals, test solutions, indicators, dyes, and reagents. It distributes chemical products to drug wholesalers, hospitals, physicians, the Veteran's Administration, and other government agencies in the United States. The company was founded by Alfred R. Globus in 1942 as United International Research Corp. and its name was changed to United Guardian, Inc. in 1987. United Guardian is based in Hauppauge, New York.
IMMUCELL CORPORATION (ICCC)
ImmuCell Corporation engages in the research and development, manufacture, and sale of diagnostic tests and products for therapeutic and preventive use against certain infectious diseases in animals and humans. It offers animal health products, including First Defense, a scours preventive product, which is manufactured from cows' colostrum using the company's vaccine and milk protein purification technologies; Wipe Out Dairy Wipes, MASTiK, and California Mastitis Test, which aid in the detection and treatment of mastitis caused by bacterial infections; Rapid Johne's Test, a test that identifies cattle with symptomatic Johne's disease; and rpt, a milk progesterone test used by dairy producers to monitor the reproductive status of their cows. The company is also developing Crypto-Scan water diagnostic test for preventing cryptosporidium parvum infections in humans, as well as Mast Out, an intramammary infusion product, as an alternative to traditional antibiotics used in the treatment of mastitis in lactating dairy cows. The company serves veterinarians and producers in the dairy and beef industries in the United States. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.